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Chapter 1. Introduction 
 
1.1 Opioid receptor 
 
Opium, a white powder obtained from the immature pericarp of the opium poppy seed (Papaver 
somniferum), has been used for pain relief since ancient times. Many alkaloids such as morphine (1), 
codeine (2), and thebaine (3) have been isolated as opiate analgesic active ingredients. These 
compounds have been named “opiate” compounds after opium in 1980s (Figure 1).1 
 
  
Figure 1. Representative opium alkaloid compounds 
 
Morphine is a central nervous system depressant and has potent analgesic and hypnotic effects on 
the human body. Further, morphine also has serious side effects: respiratory depression, physical and 
psychological dependence, and constipation.2 Thus, morphine is designated as a narcotic analgesic and 
its clinical use is limited. Therefore, many researchers have been trying to develop a strong analgesic 
without the above side effects, particularly dependence. 
A pharmacologist in the 1980s proposed three types of opioid receptors (μ, δ, and κ).3 Addiction was 
found to be caused by the μ opioid receptor (MOR).4 Thus, the δ opioid receptor (DOR) and κ opioid 
receptor (KOR) are expected to be targeted for developing analgesic agents without addiction. 
In 1982, The Upjohn Company (currently merged with Pfizer)  reported the first highly selective 
KOR agonist U-50,488H (4) (Figure 2).5 Since then, many research groups have modified the structure 
of U-50,488H to create more selective and potent KOR agonists. The U-50,488H like KOR agonists 
showed potent antinociceptive effects without morphine-like side effects, such as dependence, in animal 
models. However, all U-50,488H derivatives had serious side effects: aversion (dysphoria, and 
psychotomimetic effects (hallucination and auditory hallucination)). These led to the cessation of the 
2 
 
development of the drug in an early clinical trial stage.6 
Nagase et al. developed a KOR agonist, nalfurafine (5), which showed neither addiction nor aversion. 
Nalfurafine was applied to post-operative pain. However, because of its severe sedative effect, its 
application was eventually dropped. Nagase et al. later found an indication that nalfurafine could act as 
an antipruritic for severe itch in the case of hemodialysis patients . Nalfurafine was launched in Japan 
in 2009.7 
 
 
Figure 2. KOR agonists 
 
DOR agonists are also expected to be a potent analgesic. Many researchers have focused on the 
development of the DOR agonist SNC-80 (6)8 and its derivatives. However, the derivatives had serious 
side effects, such as convulsion and catalepsy, leading to their withdrawal at an early clinical trial stage. 
However, Nagase et al. succeeded in designing and synthesizing the first non-peptide DOR selective 
agonist TAN-67 (7),9 based on the morphinan skeleton, and KNT-127 (8),10 an improved analogue of 
the TAN-67 (Figure 3). These compounds showed none of the convulsions and catalepsy exhibited by 
SNC-80 derivatives. However, the analgesic effects were found to be insufficient for treatment, and a 
KNT-127 derivative, NC-2800 has been developed as an antidepressant and anti-anxiety drug at the pre-
clinical stage. 
 
 
Figure 3. DOR agonists  
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1.2 Synthesis of trimer compounds with a 1,3,5-trioxazatriquinane skeleton 
 
Recently, many researchers have reported the existence of receptor oligomers. Opioid receptors are 
also known to exist as homodimer or heterodimers.11 Further, some reports have described heterodimeric 
receptors composed of other different receptors such as opioid-β-adrenaline.11a),d) Based on this 
knowledge, many symmetrical and nonsymmetrical dimer ligands with two pharmacophore units have 
been reported in a variety of medicinal chemistry fields.12 Recently, Nagase et al. were found to be 
synthesized 1,3,5-trioxazatriquinane compound 12 in the process of synthesis of acetal dimer 11 from 
α-hydroxyaldehyde 10, which is derived from naltrexone methyl ether (9) (Scheme 1). The structure of 
12 was determined by X-ray crystallography.13 
 
 
Scheme 1. Discovery of 1,3,5-trioxazatriquinane compound 
 
The central nitrogen of the 1,3,5-trioxazatriquinane skeleton (trimer skeleton) was derived from 
ammonia in the solvent (saturated ammonia-CHCl3) in column chromatography. When compound 10 
was treated with NH4Cl and AcONa in MeOH under reflux temperature, oxazoline dimer 13 (45%) and 
its isomer 14 (43%) were isolated (Scheme 2). This dimer 14 was treated with dl-camphorsulfonic acid 
(CSA) in CHCl3 under reflux temperature to give a mixture of trimer 12 (30%) and dimer 13 (30%). 
However, dimer 13 was converted to trimer 12 in 68% yield under the same condition (Scheme 2). 
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Scheme 2. Optimized synthesis of the 1,3,5-trioxazatriquinane skeleton 
 
Nagase et al. reported a general synthetic method for the trimer compounds from a broad range of 
ketones (Scheme 3).13 Initially, ketone 15 was treated with 1,3-dithiane and followed by treatment with 
copper (II) reagents to afford α-hydroxyaldehyde 17. The obtained 17 was converted into oxazoline 
dimer 18 by treating with NH4Cl in the presence of AcONa. After isolating oxazoline dimer 18 as a 
diastereomer mixture, 18 was converted to 1,3,5-trioxazatriquinane compound 19 under acidic 
condition. 
 
 
Scheme 3. Synthetic methods of trimer compound 19 
 
However, this method for the synthesis of α-hydroxyaldehyde 17 required the expensive dithiane, 
the hazardous n-butyllithium, and low temperature conditions (-78 ºC). Thus, the 2nd generation 
synthetic method was established (Scheme 4).14 Ketone 15 was treated with p-toluenesulfonylmethyl 
isocyanide (TosMIC) at room temperature in the presence of K2CO3 to give tosyloxazoline intermediate 
20, this was followed by the hydrolysis of 20 with HCl aq. to afford α-hydroxyaldehyde 17.15 This 
method produced the important intermediate 17 without the need for any expensive or hazardous 
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reagents and low temperatures. 
 
Scheme 4. General synthetic method of 1,3,5-trioxazatriquinane compounds 
 
Using the 2nd generation synthetic method for 17, Nagase et al. also achieved the synthesis of 
heterotrimer derivatives (Scheme 5, route A).13 Heterotrimer 19′, bearing two identical substituents 
and one different substituent, was synthesized via a reaction of oxazoline dimer 18 and a different α-
hydroxyaldehyde 17′. Moreover, heterotrimer 19′′, bearing three different substituents was synthesized 
through a reaction of 17′′ and hetero-oxazoline dimer 18′ (derived from 17 and protected α-
hydroxyaldehyde 21) (Scheme 5, route B).16 
 
 
Scheme 5. Synthesis of trimer compounds bearing different substituents 
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1.3 Structural features of 1,3,5-trioxazatriquinane derivatives 
 
The general structure of a trimer is shown in Figure 4. The 1,3,5-trioxazatriquinane skeleton is rigid 
and its side chains are oriented to the six different directions. The trimer skeleton contains one nitrogen 
atom at the center of the skeleton together with three oxygen atoms; this is expected to be playing the 
role of a pharmacophore unit. 
 
 
Figure 4. General structure of 1,3,5-trioxazatriquinane compound 
 
Based on the aforementioned structural features, trimer compounds can be applied in the following: 
i) chemical library, ii) synthesis of twin or triplet ligands consisting of several bioactive compounds, 
and iii) use as a pharmacophore unit (Figure 5). 
 
 
Figure 5. Application of trimer compounds 
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1.4 Application of the trimers to chemical library 
 
The original lead compounds are essential for the development of pharmaceutical compounds. Many 
pharmaceutical companies purchase chemical libraries consisting of the tens of thousands to mill ions 
of compounds by paying a huge amount money. These commercial chemical libraries consist of raw 
material for the production of chemical products and synthesized compounds by combinatorial 
chemistry. Therefore, the diversity of the structures is poor and they sometimes contain harmful and 
toxic compounds, which are not drug-like compounds that can be optimized to lead compounds. 
Consequently, the hit rate of screening with such chemical libraries tends to be lower.17 These facts 
indicate that an inexpensive chemical library with a high hit ra te is considerably important for the 
efficient drug development. In particular, the construction of inexpensive and drug-like chemical library 
is more important for drug discovery to decrease the development risk and cost, especially in 
universities and small and medium-sized pharmaceutical companies. 
The hit compounds found by screening using the chemical library cause pharmacological action  by 
binding with biological macromolecules. Therefore, the pharmacophore units are needed to be oriented 
to the appropriate spaces to bind with receptors, enzymes, and so on. To construct a high hit rate 
chemical library, it is necessary to collect compounds with appropriate side chains oriented to various 
directions. 
 
 
Figure 6. The trimer compounds with appropriate side chains oriented to various directions 
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The above-mentioned trimer compounds respond to the requirements for the chemical library with 
a high hit rate. Also, they can be synthesized from general ketones in four steps. Further, more than 16 
types of compounds with a trimer skeleton, including optical isomers, can be synthesized at a time. In 
particular, since phenethylamine units, which are essential pharmacophore units for neurotransmitters, 
can be easily introduced to the side chain, the resulting libraries can be expected to have a high hit rate 
for neurotransmitter receptors (Figure 7). 
 
 
Figure 7. Representative neurotransmitters bearing the phenethylamine moiety, and  
1,3,5-trioxazatriquinane skeleton having a phenyl group 
 
To verify the usefulness of the chemical libraries composed of the trimer ligands, Nagase et al. 
constructed the trimer library that consisted of 64 compounds and evaluated the affinity for opioid 
receptors (Figure 8).18 Surprisingly, the hit ratio of screening with this library was 14% (9 in the 64 
compounds). The trimer derivatives with a phenethylamine moiety showed high affinity for opioid 
receptors. Especially, mono-capped trimers with a cap structure (oxamethylene cap-like structure) 
showed a high hit rate. A mono-capped trimer with the m-phenolic hydroxyl group, SYK-146 (25)19 
(Figure 9), was found to be a highly selective and potent agonist for KOR, the activity nearly equivalent 
to that of U-50,488H (4). These results indicate that the chemical library consisting of trimer compounds, 
particularly mono-capped trimer compounds would be useful for highly efficient ligand screening.  
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Figure 8. Trimer compound libraries showed a high hit rate for opioid receptors  
 
 
Figure 9. Structure of mono-capped trimer compound SYK-146 
  
Binding at 1000 nM or less Binding at several nM or lessBinding at several mM
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1.5 Trimer compounds to apply to twin and triplet drugs 
 
Twin drug is defined as hybrids of two pharmacophore units conjugated through a linker. 12 Twin 
drug bearing the same pharmacophore unit is called a symmetrical twin drug, whereas that possessing 
different pharmacophore units is called nonsymmetrical twin drug (Figure 10). A symmetrical twin 
drug is expected to improve the activity and/or selectivity more than a corresponding monomer drug 
(Figure 10a). However, a nonsymmetrical twin drug is expected to show dual action to interact with 
different receptors (Figure 10b).20 Further, twin drugs can play only one role: either increased 
pharmacological activity or dual action. On the contrary, a triplet drug may exhibit both increased 
pharmacological action and dual action (Figure 10c). 
 
    
Figure 10. Twin drugs and triplet drug 
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As aforementioned, the trimer compounds can be synthesized from various ketones. Therefore, the 
various pharmacophore units can be introduced to a trimer skeleton to afford twin and triplet drugs. 
Synthesized triplet drugs bearing morphinan skeletons are shown in Figure 11.  
 
Figure 11. Structures of twin and triplet drugs with morphinan skeletons  
 
The triplet drug with three morphinan skeletons, KNT-93 (26), showed a high affinity for MOR and 
approximately 20 times more potent analgesic activity than morphine (1) in a mice acetic acid writhing 
test.13 The twin drug with two morphinan skeletons, KNT-123 (27), showed highest selectivity for MOR 
to KOR. Because such a highly selective MOR ligand has not yet been reported, 27 would be useful for 
clarifying the real pharmacological effects of MOR.  
 
  
12 
 
1.6 The use of a trimer skeleton as the pharmacophore unit  
 
There are one basic nitrogen atom and three oxygen atoms in the 1,3,5-trioxazatriquinane skeleton. 
Therefore, the skeleton itself is expected to participate, as a pharmacophore unit, in an interaction with 
the receptor. KNT-379 (29),21 an oxymorphone (28) derivative fused with the 1,3,5-trioxazatriquinane 
skeleton, showed significant activity and selectivity changes for each opioid receptor (Figure 12). This 
fact supports the usefulness of this skeleton as a pharmacophore unit.  
 
 
Figure 12. Oxymorphone derivative with a trimer pharmacophore unit  
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1.7 The synthetic plans of 1,3-dioxa-5-thiazatriquinane and 1-oxa-3,5-dithiazatriquinane 
derivatives and their pharmacologies 
 
Since the discovery of 1,3,5-trioxazatriquinane compounds, the trimer compounds containing 
heteroatoms other than oxygen and nitrogen atoms in the trimer skeleton have not been synthesized. In 
this thesis, the author describes the synthesis of novel trimer compounds bearing sulfur atom(s) to 
investigate the substitution effect of oxygen atom(s) with sulfur atom(s) in the 1,3,5-trioxazatriquinane 
skeleton (Chapter 2) (Figure 13). 
 
 
Figure 13. Substitution of oxygen atom with sulfur atom in a trimer skeleton  
 
In the course of the synthetic study of 1,3,5-trithiazatriquinane derivatives from corresponding 
thioacetophenones, the author unexpectedly found the production of an adamantane -like compound 
consisting of phosphorus, sulfur, and carbon atoms under sulfurization conditions of acetophenone 
derivatives with P4S10 (Figure 14). To the best of the authors’ knowledge, this adamantane-like 
compound has not thus far been reported. Herein, in Chapter 3, the author describes the structure and 
synthetic method of the adamantane-like compounds. 
 
 
Figure 14. Discovery of a novel adamantane-like compound   
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Chapter 2. Synthesis of 1,3-dioxa-5-thiazatriquinane and 1-oxa-3,5-dithiazatriquinane derivatives, 
and their pharmacologies 
 
2.1 Design of trimer compounds containing sulfur atom(s) 
 
As described in Chapter 1, the chemical library composed of the mono-capped trimer compounds 
with phenethylamine moiety showed a high hit rate. In general, the basic nitrogen in bioactive 
compounds was believed to be an essential pharmacophore unit for binding to receptor sites, not only 
opioid receptors but also other receptors. Therefore, a basic nitrogen atom in the center of the trimer 
skeleton would play an important role in binding to receptors. However, the basicity of the nitrogen in 
the 1,3,5-trioxazatriquinane skeleton was found to be significantly weaker than that of a general tertiary 
amine (triethylamine) in the calculation with ADMET Predictor,19a) because of the strong electron 
withdrawing abilities of the three oxygen atoms in the skeleton. Therefore, the author designed the 
sulfur-containing trimer derivatives expecting an increase in the basicity of the nitrogen atom by 
substituting the sulfur atom for oxygen atoms. Furthermore, the author predicted the structural changes 
in the sulfur-containing trimer compounds based on the difference in the lengths of the O–C (143 pm) 
and S–C bonds (182 pm).22 These changes would also affect the activity and/or selectivity for each 
opioid receptor type. The author synthesized trimer compounds having sulfur atom(s) in place of oxygen 
atom(s) and evaluated their pharmacological activities  (Figure 15). 
 
 
Figure 15. Trimer compounds having sulfur atom(s) in place of oxygen atom(s)  
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2.2 Synthesis of 1,3-dioxa-5-thiazatriquinane compounds 
 
The synthetic strategy of monothiotrimer compound 31 was shown in Scheme 6. The sulfur atom 
would be introduced at the last stage of synthesis by using the α-mercaptoaldehyde 30 instead of α-
hydroxyaldehyde. 
 
Scheme 6. Synthetic strategy of monothiotrimer compound 
 
At first, 3′-methoxyacetophenone (32) was treated with TosMIC in the presence of K2CO3, and then 
2 M HCl aq. to afford α-hydroxyaldehyde 33 (Scheme 7). Without any purification of the obtained 33, 
it was converted into the oxazoline intermediates 34 by treatment with NH4Cl and AcONa. Mono-
capped trimer compounds 35a−d were finally prepared by acidic condensation of 34 with 2,5-
dihydroxy-1,4-dithiane. These diastereomers were separated by silica gel column chromatography.  
 
 
Scheme 7. Synthesis of mono-capped trimer compounds having one sulfur atom 
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Next, the O-methyl group of 35b, which have the same stereochemistry as that of SYK-146 (Figure 
9), was removed with potassium 1-propanethiolate to give 36b (Scheme 8). 
 
 
Scheme 8. Deprotection of O-methyl group 
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2.3 Pharmacological effect of 1,3-dioxa-5-thiazatriquinane compound 
 
To confirm the effect of sulfur substitution on the trimer compounds, the binding affinities of the 
36b for the opioid receptors were evaluated with competitive binding assays (Table 1). 
The compound 36b showed lower affinity for KOR than SYK-146 (25), that is, the replacement of 
only one oxygen atom by a sulfur atom induced almost 20 times lower affinity for the KOR. The author 
confirmed that the replacement of the oxygen atom by the sulfur atom resulted in a change in the affinity. 
This time, only the affinity for the opioid receptor was evaluated. Improved activity for other receptors 
is expected. The trimer library composed of sulfur atoms is expected to be a new chemical library series. 
 
Table 1. Binding affinities of SYK-146 (25) and 36b for opioid receptors a 
 
compounds 
Ki (nM) 
μb δc κd 
SYK-146 >1000 >1000 6.09 
36b >1000 >1000 110 
a Ki values with 95% confidential intervals were obtained from radioligand-based competitive receptor binding assay. 
b [3H]DAMGO was used. c [3H]DPDPE was used. d [3H]U-69,593 was used. 
 
In addition, synthesis of the capped trimer with three sulfur atoms was also investigated. However, 
many trials to convert the ketone group of the acetophenone into the corresponding thioketone group 
failed because of the instability of the resulting thioketone. However, the author happened to discover 
a method to synthesize novel adamantane-like compounds during the course of the trials to obtain the 
thioketone. The details will be described in Chapter 3.  
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2.4 Synthesis of 1,3-dioxa-5-thiazatriqinane and 1-oxa-3,5-dithiazatriquinane compounds having 
a morphinan skeleton 
 
As the author could not obtain the thioketone derivatives from acetophenones, the author tried to 
introduce more sulfur atoms to the double-capped trimer skeleton, starting from naltrexone. 
Nagase et al. have reported the synthesis of double-capped trimers SYK-134 ((R)-37) and SYK-135 
((S)-37) from naltrexone.21 Both derivatives showed high affinities for opioid receptors. Interestingly, 
(R)-37 showed agonistic activity for KOR, whereas (S)-37 had antagonistic activities for MOR and 
KOR (Figure 16). These trimers have a 1,3,5-trioxazatriquinane skeleton with two cap structures bound 
with the 4,5-epoxymorphinan structure, and the 1,3,5-trioxazatriquinane moiety itself is considered to 
play the role of the pharmacophore unit. 
This time, the author attempted to introduce one and two sulfur atoms to the cap structure moiety in 
the trimer and examined the effects on the activity of the obtained trimers. 
 
 
Figure 16. Structure of double-capped trimers, SYK-134 ((R)-37) and SYK-135 ((S)-37) 
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First, according to the method of synthesizing monothiotrimer compound 35 described in the 
previous section, synthesis of the morphinan derivatives having two cap structures with introduced one 
sulfur atom was attempted (Scheme 9). Naltrexone methyl ether (9) was treated with TosMIC in the 
presence of K2CO3, and the resulting oxazoline intermediate was hydrolyzed with 2 M HCl aq. to afford 
the α-hydroxyaldehyde 10. Without any purification of the obtained 10, it was converted into the 
hydroxymethyl oxazoline intermediates 38 as diastereomer mixtures in 50% yields from 9. Then, the 
obtained 38 was reacted with 2,5-dihydroxy-1,4-dithiane under acidic conditions to give unexpected 
diastereoisomer mixtures (R)-41 and (S)-41 bearing two sulfur atoms, but not the target compounds 39. 
The reason for this is considered to be the fact that the oxazoline 38 would be hydrolyzed into 
iminoaldehyde 40 under the acidic conditions, and the resulting 40 would react with an excessive 
amount of 2,5-dihydroxy-1,4-dithiane to afford the mixtures of 41. 
 
 
Scheme 9. An attempt to synthesize monothiotrimers  39 
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Therefore, next, the author tried to synthesize the regioisomeric monothiotrimers (Scheme 10, 11).23 
The obtained 10 from naltrexone methyl ether (9) was treated with 2,5-dihydroxy-1,4-dithiane in the 
presence of NH4Cl and AcONa to afford mercaptomethyl oxazoline intermediates (R)-42 and (S)-42 in 
24% and 22% yields from 9, respectively.  
 
 
Scheme 10. Synthesis of methylthiooxazolines 42 
 
The reactions of each of the (R)-42 and (S)-42 with glycolaldehyde dimer afforded the 1,3-dioxa-5-
thiazatriquinane compounds (R)-43 in 55% and (S)-43 in 57% yields, respectively (Scheme 11). The 
demethylation of (R)-43 and (S)-43 with nPrSH and tBuOK gave the corresponding phenolic 
compounds (R)-44 in 83% and (S)-44 in 83% yields, respectively. 
 
 
Scheme 11. Synthesis of monothiotrimers 44 
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In addition, the alternative synthetic method of 1-oxa-3,5-dithiazatriquinane compound 41 was 
established utilizing the intermediates 42. The reactions of (R)-42 and (S)-42 with 2,5-dihydroxy-1,4-
dithiane afforded the 1-oxa-3,5-dithiazatriquinane compounds (R)-41 in 50% and (S)-41 in 48% yields, 
respectively. The demethylation of the resulting (R)-41 and (S)-41 gave (R)-45 and (S)-45, respectively 
(Scheme 12). 
The stereochemistries of the trimer compounds (R)-43, (R)-43, (S)-41, and (S)-41 were determined 
by the NOESY experiments depicted in Figure 17. 
 
 
Scheme 12. Synthesis of dithiotrimer 45 
 
 
Figure 17. Observed NOESY correlations in the trimer compounds (R)-43, (R)-41, (S)-43, and (S)-41 
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2.5 Pharmacological effects of the sulfur-containing trimer compounds 
 
Next, the author evaluated the binding affinities and agonistic and antagonistic activities of the 
obtained compounds, (R)-44, (R)-44, (S)-45, and (S)-45, for the opioid receptors with competitive 
binding assays and [35S]GTPγS-binding assays. The assays were performed according to a previously 
reported procedure24 and the results were shown in Table 2. As expected, the affinities of all of the 
obtained thio-derivatives for the opioid receptors were higher than those of the double-capped 1,3,5-
trioxazatriquinane compounds SYK-134 ((R)-37) and SYK-135 ((S)-37). However, the µ/κ ratios of all 
the thiotrimer compounds decreased. Moreover, the δ/κ ratios of the R isomers were higher than those 
of the S isomers. The most important influence of the introduced sulfur atoms was the interconversion 
between agonistic and antagonistic activities. That is, although SYK-134 ((R)-37) was the agonist for 
the KOR, the (R)-44 with one sulfur atom and (R)-45 with two sulfur atoms were antagonists for MOR 
and KOR (Figure 18). On the other hand, the antagonist SYK-135 ((S)-37) for MOR and KOR, was 
converted to partial agonists (S)-44 and (S)-45 for the MOR and DOR, respectively.  
 
Table 2. Pharmacological activities of synthesized trimer compounds to opioid receptor  a 
a Ki values with 95% confidence intervals were obtained from radioligand-based competitive receptor binding assay. 
b [3H]DAMGO was used. c [3H]DPDPE was used. d [3H]U-69,593 was used. 
 
 
compounds 
Ki (nM) selectivity 
µb δc κd µ/κ δ/κ 
SYK-134 8.65 99.8 3.86 2.24 25.9 
(R)-44 2.78 60.9 1.41 1.97 43.2 
(R)-45 2.69 248 1.94 1.39 128 
SYK-135 6.85 78.6 5.95 1.15 13.2 
(S)-44 3.23 26.0 3.21 1.00 8.10 
(S)-45 1.96 17.1 9.08 0.21 1.88 
23 
 
 
Figure 18. Pharmacological activities of synthesized trimer compounds to opioid receptor  
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2.6 Conclusion of Chapter 2 
 
In conclusion, the author tried to convert the oxygen in the trimer skeleton to a sulfur atom to 
examine the effect of the activity and affinity according to changes in the basicity of the central nitrogen 
and the bond length between oxygen and sulfur. As a result, the isolated mercaptomethyl oxazoline 
intermediates 42 were found to contribute to the conversion of the oxygen atom to the sulfur atom in 
the trimer moieties. The obtained mono and dithiotrimers were evaluated their binding affinities and 
the [35S]GTPγS assay for the opioid receptors. The assay results showed that the substitution of the 
sulfur atom(s) for the oxygen atom(s) played the role of changing the pharmacological profiles: 
increasing the affinities for the opioid receptors and interconversion between agonist ic and antagonistic 
activities. These changes in the activities could be derived from the differences in the electron density 
on the central nitrogen or the bond length between the oxygen and sulfur atoms.  
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Chapter 3. Synthesis of sulfur and phosphorus-containing adamantane-like compounds 
 
3.1 Synthetic study of 1,3,5-trithiazatriquinane compound and discovery of sulfur-containing 
adamantane-like compound 
 
Since the influence on the pharmacological activity by introducing sulfur atom(s) into the trimer 
skeleton was confirmed in Chapter 2, the synthesis of 1,3,5-trithiazatriquinane compound (trithiotrimer 
compound) was next attempted (Scheme 13). Trithiotrimer compound 49 is expected to be synthesized 
from three α-mercaptoaldehyde 47, which might be obtained from thioketone 46. For this reason, the 
author examined the synthesis of thioketone 46.  
 
 
Scheme 13. Synthetic plan of trithiotrimer compounds 
 
The proposed synthetic route of trithiotrimer compounds is shown in Scheme 14. The representative 
sulfurizing reagents are P4S1025 and Lawesson's reagent,26 and the latter has tended to be used more 
frequently due to its solubility and better yields. However, these reagents led to a complex mixture 
(entries 1 and 2 in Table 3). Next, the reaction condition was attempted using P4S10 as a sulfurizing 
reagent in carbon disulfide, in the presence of triethylamine, to give a complex mixture (entry 3). Next, 
the reaction of 31 with 10 equivalents of P4S10 for 20 h in refluxing benzene afforded a complex mixture. 
However, after filtration of the reaction mixture, the resulting crude crystal was recrystallized from 
chloroform to give a colorless crystal. The 1H NMR and 13C NMR spectra of the obtained compound 
suggested the disappearance of a methyl group and a connection between a phosphorus and a carbon. 
The 31P NMR spectrum showed the existence of two equivalent phosphorus atoms and another 
phosphorus atom at 56.7 and 62.0 ppm, respectively. Finally, the X-ray crystallography revealed the 
structure of the obtained compound as a novel adamantane-like compound 53 (Figure 19).27  
26 
 
 
Scheme 14. An attempt to synthesize trithiotrimer 50 and the discovery of novel adamantane-like 
compound 53 
 
Table 3. Results of sulfurization of 3′-methoxyacetophenone (32) 
 
 
Figure 19. ORTEP drawing of 53 
 
  
entry reagent solvent temperature product 
1 Lawesson’s reagent (1.5 eq.) benzene reflux complex mixture 
2 Lawesson’s reagent (1.5 eq.) toluene reflux complex mixture 
3 P4S10 (3.0 eq.), Et3N (10 eq.) CS2 reflux complex mixture 
4 P4S10 (10 eq.) benzene reflux 53 (39%) 
27 
 
3.2 Optimization of reaction conditions for synthesis of adamantane-like compound 
 
The synthesis of adamantane-like compound 55a using acetophenone (54a) was examined in the 
same manner as that of 53 (Scheme 15). Acetophenone (54a) was treated with 10 equivalents of P4S10 
in refluxing benzene for 20 h. The resulting reaction mixture was filtered through a glass filter followed 
by recrystallization from chloroform to give the desired colorless crystal. The structure of 55a was 
determined by X-ray crystallography (Figure 20). 
 
 
Scheme 15. Synthesis of 55a 
 
 
Figure 20. ORTEP drawing of 55a 
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As the conversion of acetophenone (54a) to the corresponding adamantane-like compound 55a was 
confirmed, the author attempted to optimize the reaction conditions to afford 55a.  
Initially, the effects of the solvent were investigated (entries 1–5 in Table 4). The yield of 55a was 
higher in toluene (52 %) than in benzene (46 %) under reflux. However, decomposition of 55a was 
observed in NMR analysis. Moreover, the yield of compound 55a was extremely low in xylene, which 
was assumed to arise from the decomposition of 55a itself at high temperature (entry 3). Also, 
halogenated solvents like carbon tetrachloride and 1,2-dichloroethane lowered the yield to afford 
complex mixtures (entries 4 and 5). 
 
Table 4. Optimization of reaction conditions 
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Next, to examine the thermal stability of 55a, temporal changes of 55a in benzene and toluene under 
reflux were observed using NMR spectrum (Figure 21). As a result, the extra peaks derived from the 
decomposition of 55a were observed in the reaction in toluene for 10 h.  On the other hand, significant 
decomposition was not observed under benzene reflux condition even after 36 h. Therefore, benzene 
was selected as the solvent for further examination.  
 
 
Figure 21. The thermal stability of 55a 
 
The reaction time for 20 h afforded higher yields of 55a than those for 4 h and 60 h (entries 1, 6, 
and 7 in Table 4). Next, the equivalent amounts of P4S10 were examined (entries 1, 8, and 9). The 1.0 
equivalent of P4S10 gave only trace amounts of the desired 55a together with 2,5-diphenylthiophene 
(56) in 16% yield as a by-product (entry 8).28 In contrast, the 5.0 equivalents of P4S10 afforded almost 
the same yield of 55a as that of entry 1 (entry 9). In addition, the lower temperature (60 ºC) gave 
extremely low yields (entries 10 and 11). Base on the above examinations, the optimal synthetic 
conditions for adamantane-like compound 55 would be the following condition: 10 equivalents of P4S10, 
under reflux in benzene for 20 h.  
As for physical properties, the adamantane-like cage compound 55a was sensitive to polar solvents 
such as THF, DMF, acetone, methanol, and DMSO, although 55a was fairly stable and storable at room 
temperature for at least 2 months under an argon atmosphere.   
in toluene 10 h
in benzene 36 h 
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3.3 Synthesis of adamantane-like compound derivatives 
 
After determining the optimized reaction conditions, the author tried to synthesize the adamantane -
like compound derivatives by the reaction of acetophenone derivatives 54 with P4S10 (Table 5). The 
tendencies of these reactions were as follows: i) the reactions of 2′-substituted 54b–d gave 55b–d in 
relatively low yields, although the reaction of 54e gave no detectable compounds (entries 1–4); ii) the 
reactions of 3′-substituted acetophenones, gave the corresponding 55 in relatively high yields (entries 
5–8); iii) the reactions of 4′-substituted 54j, 54l, and 54m afforded 2,4-bis(4-methoxyphenyl)thiophene 
(57j),29 2,5-bis(4-bromophenyl)thiophene (58l),28b),28c),28e),28h) and 2,5-bis(4-nitrophenyl)thiophene 
(58m),30 respectively (entries 9, 11, and 12). All the NMR spectra of these derivatives 55b–55m 
corresponded to that of 55a. Interestingly, the 31P NMR showed that the chemical shifts of the 
phosphorus atoms are affected by the electron-withdrawing group on the phenyl group (55a: 56.7, 62.0 
ppm, 55h (3′-Br): 55.7, 60.9 ppm, 55i (3′-NO2): 54.8, 60.1 ppm, 55l (4′-Br): 56.0, 61.3 ppm), although 
the substituent and the phosphorus atoms are relatively distant from each other. 
 
Table 5. Synthesis of the adamantane-like compounds 55 
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The X-ray structures of 55c (Figure 22) bearing an electron-donating group and 55i (Figure 23) 
bearing an electron-withdrawing group revealed that both derivatives also have the corresponding 
adamantane-like skeleton.  
 
 
Figure 22. ORTEP drawing of 55c 
 
 
Figure 23. ORTEP drawing of 55i 
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3.4 Postulated reaction mechanism for the formation of adamantane-like compound 
 
The plausible reaction mechanisms for the formation of 55 are illustrated in Scheme 16 although the 
reactivity of P4S10 is considerably complicated and not yet fully clarified.26a),31 Path A is based on the 
in situ formation of thioacetophenone. In the presence of refluxing solvents, P4S10 is converted to P2S5 
(I) that produces the desired thioacetophenone through the formation of a four-membered ring 
compound, II.26a),31a),31c),31f),32 Because the thiocarbonyl group tends to form a stable C–S bond,33 the 
more reactive en-thiol form of thioacetophenone immediately reacts with the fragments I or III, and the 
generated IV recombines with I to form 55. On the other hand, path B is based on the direct reaction 
of acetophenone with P4S10.34 In this plausible pathway, the temporary sulfurization of acetophenone 
occurs in P4S10-mediated species, and the following reassembly of the adamantane-framework gives 55. 
 
 
Scheme 16. Possible mechanism for the formation of 55  
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3.5 Discovery of a novel noradamantane-like compound 
 
As described in Section 3.3, because the yields of 2′-substituent adamantane-like compounds 55 
decreased in benzene, 2′-methoxyacetophenone (54b) was subjected to react with P4S10 under toluene 
reflux to improve the yield of 55b. As a result, a novel noradamantane-like cage compound 59 without 
one sulfur atom of 55b was obtained (Scheme 17). The structure of 59, consisting of phosphorus, sulfur, 
and carbon atoms, was determined by X-ray crystallographic analysis (Figure 24). 
To the best of the authors’ knowledge, only a few noradamantane skeletons consisting of three 
elements such as Si, S, and C atoms35; Se, S, and C atoms35; C, N, and O atoms36; Ge, Si, and S atoms37; 
or Sn, Si, and Se atoms37 were reported. 
 
 
Scheme 17. Synthesis of novel noradamantane-like compound 59 
 
 
Figure 24. ORTEP drawing of 59 
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3.6 Application of adamantane-like compounds as sulfurization reagents 
 
The structures of these adamantane-like compounds 55 are quite similar to that of P4S10. However, 
compounds 55 were odorless, which is different from P4S10 and Lawesson’s reagent. Moreover, these 
compounds dissolved satisfactorily in benzene or toluene but P4S10 did not. In addition, the author 
compared the sulfurization of 4,4′-dimethoxybenzophenone (60) using the adamantane-like compound 
55a, with that of P4S10, and Lawesson’s reagent (Table 6). Although the reaction using 55a needed a 
longer time to complete the reaction as compared to that using P4S10 and Lawesson’s reagent, it gave 
thioketone 61 in a higher yield. 
 
Table 6. Sulfuration of 4,4′-dimethoxtbenzophenone (60) 
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Next, the author examined the sulfurization of the amide group in N,N′-dimethylbenzamide (62) 
(Table 7). Although the reaction time of 55a was longer, the yields of thioamide 63 were higher than 
those obtained by using P4S10 and Lawesson’s reagent. Therefore, considering its solubility and 
odorlessness, 55 can be a good sulfurization agent. 
 
Table 7. Sulfurization of N,N′-dimethylbenzamide (62) 
 
 
On the other hand, the reaction of 60 using the noradamantane-like compound 59 did not complete 
under the same condition of the sulfurization reaction that used 55a. The thioketone 61 was obtained in 
only 14% yield and the starting material 60 was recovered in 83% (Scheme 18).  
 
 
Scheme 18. Sulfuration of 4,4′-dimethoxtbenzophenone (60) by using 59 
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3.7 Conclusion of Chapter 3 
 
In conclusion, the author synthesized novel adamantane-like compounds 55 and the noradamantane-
like compound 59 consisting of the three elements—phosphorous, sulfur, and carbon—by the reactions 
of acetophenone derivatives 54 with P4S10. In addition, by the reaction with 55a, ketone and benzamide 
were successfully transformed to the corresponding thioketone and thioamide, respectively, in high 
yields. The obtained 55a was soluble in solvent and odorless different from P4S10. Therefore, 
considering its solubility and odorlessness, 55a is expected to be a good sulfurization reagent. 
 
  
37 
 
Chapter 4. Conclusion 
 
In this article, the author focused on the 1,3,5-trioxazatriquinane skeleton and synthesized the 
trimers having the sulfur atom(s) in place of the oxygen atom(s) to improve their affinities for receptors 
and pharmacological activities. Therefore, the author established the synthetic methods of 1,3-dioxa-5-
thiazatriquinane compounds, which contained one sulfur atom, and 1-oxa-3,5-dithiazatriquinane 
compounds, which contained two sulfur atoms, by using 2,5-dihydroxy-1,4-dithiane instead of α-
hydroxyaldehyde. 
The assay results of thiotrimers for the opioid receptors showed that the substitution of the sulfur 
atom(s) for the oxygen atom(s) effected the affinities for the opioid receptors and affected the expression 
of the agonistic activities (Figure 25). The configuration of the central skeleton changed because of the 
introduction of the sulfur atoms, and electronic factors due to reduced electronegativity also changed. 
 
 
Figure 25. Affinities for opioid receptors and activities of thiotrimer compounds 
 
Also, in the process of the synthesis of 1,3,5-trithiazatriquinane compound, the author found to be 
synthesized the novel adamantane-like compound 55 (Figure 26). Because there have been no reports 
of such a compound containing three elements of phosphorus, sulfur, and carbon in an adamantane 
skeleton, the structure of this compound was very fascinating. Furthermore, the novel noradamantane-
like compound 59 obtained by the optimization of the reaction condition was also a very fascinating 
compound that has not been previously reported. In addition, the adamantane-like compound 55a was 
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found to be a good sulfurization agent. The adamantane-like compounds 55, which are odorless and are 
soluble in organic solvents, are expected to represent a new-generation of sulfurization reagents. 
 
 
Figure 26. Novel adamantane-like compound and noradamantane-likecompound 
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Experimental section 
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General  
All melting points were determined on a Yanaco MP melting point apparatus and are uncorrected. 
Infrared spectra were recorded with a JASCO FT/IR 4100 spectrophotometer. 1H, 13C, and 31P NMR 
spectral data were obtained with JEOL JNM-ECS 400 instruments. Chemical shifts are quoted in ppm 
using tetramethylsilane (δ = 0 ppm) as the reference for 1H NMR spectroscopy, CDCl3 (δ = 77.0 ppm) 
for 13C NMR spectroscopy, and 85% H3PO4 (δ = 0 ppm) for 31P NMR spectroscopy. Mass spectra were 
measured with a JEOL JMS-T100LP spectrometer. Elemental analysis was performed with a Yanaco 
CHN-CODER JM-10 model analyzer. Column chromatography was carried out on silica gel (spherical, 
neutral, 40–50 µm, Kanto Chemical Co., Japan). 
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Chapter 2.  
 
2,4-Bis(3-methoxyphenyl)-2,4-dimethyl-1,3-dioxa-5-thiaza-triquinane (35a–d) 
 
Under Ar atmosphere, m-methoxyacetophenone (32, 0.50 mL, 3.65 mmol), p-toluenesulfonylmethyl 
isocyanide (1.47 g, 7.53 mmol), and K2CO3 (1.00 g, 7.24 mmol) were suspended in MeOH (10 mL) and 
stirred at rt for 3 h. After concentration of reaction mixture, residue was poured into distilled water (20 
mL) and extracted with CHCl3 (20 mL, 10 mL, 5 mL). The combined organic layers were washed with 
brine (10 mL), dried over anhydrous Na2SO4 and evaporated in vacuo. The crude product was resolved 
in THF (5 mL). To the solution was added 2 M HCl aqueous solution (7 mL) and stirred at rt for 2 h. 
The reaction mixture was neutralized with K2CO3 to pH 9 and extracted with CHCl3 (15 mL, 10 mL, 
5mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na 2SO4 and 
evaporated in vacuo. The obtained crude product was used in next reaction without further purification.  
Under Ar atmosphere, the crude product, NH4Cl (0.332g, 6.21 mmol), and AcONa (1.02 g, 12.4 mmol) 
were suspended in MeOH (6 mL) and refluxed with stirring for 3 h. The reaction mixture was poured 
into saturated NaHCO3 aqueous solution (15 mL), and extracted with CHCl3 (15 mL, 10 mL, 5 mL). 
The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4 and then 
evaporated in vacuo. The residue was purified by silica gel column chromatography (Hexane: EtOAc = 
4:1) to afford a mixture of oxazoline dimer 34 (0.263 g) as yellow oil, which was used in next reaction 
without further purification. 
The solution of oxazoline dimer 34, 2,5-dihydroxy-1,4-dithiane (1.67 g, 11.0 mmol), and CSA (5.11 g, 
22.0 mmol) in CHCl3 (5 ml) was stirred at rt for 3 h under Ar atmosphere. The reaction mixture was 
poured into saturated NaHCO3 aqueous solution (10 mL) and extracted with CHCl3 (15 mL, 10 mL × 
2). The combined organic layers were washed with braine (10 mL), dried over anhydrous Na 2SO4 and 
then evaporated in vacuo. The residue was purified by silica gel column chromatography 
(Hexane:EtOAc = 8:1) to give 35a (131 mg, 9% from 32), 35d (72.9 mg, 5% from 32) as colorless 
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amorphous materials and mixture of 35b and 35c. The mixture was purified by preparative TLC 
(Benzene:EtOAc = 10:1) to afford 35b (87.5 mg, 6% from 32) and 35c (87.7 mg, 6% from 32) as a 
colorless amorphous material, respectively. 
 
rac-(2S,2aS,4S,4aS,6aS)-2,4-Bis(3-methoxyphenyl)-2,4-dimethyl-1,3-dioxa-5-thiaza-triquinane 
(35a): 
HR-MS (ESI): m/z Calcd for C22H26NO4S [M+H]+: 400.1583. Found: 400.1571. 
IR (film, cm-1): 2998, 2933, 2834, 1601, 1583, 1485.  
1H NMR (400 MHz, CDCl3): δ 1.68 (s, 3H), 1.73 (s, 3H), 3.22 (dd, J = 12.8, 3.0 Hz, 1H), 3.33 (d, J = 
12.8 Hz, 1H), 3.79 (s, 3H), 3.83 (s, 3H), 5.11 (d, J = 3.0 Hz, 1H), 5.13 (s, 1H), 5.38 (s, 1H), 6.77 (ddd, 
J = 8.2, 2.6, 0.9 Hz, 1H), 6.80 – 6.84 (m, 1H), 6.92 (ddd, J = 7.7, 1.7, 1.0 Hz, 1H), 6.94 – 6.96 (m, 1H), 
6.99 – 7.04 (m, 2H), 7.25 (dd, J = 8.0, 8.0 Hz, 1H), 7.30 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ 24.3, 27.4, 38.3, 55.40, 55.42, 81.8, 85.7, 86.4, 98.2, 100.4, 111.0, 111.6, 
112.1, 112.6, 117.1, 117.7, 129.6, 129.9, 144.8, 145.7, 159.8, 160.0. 
 
rac-(2S,2aS,4R,4aS,6aS)-2,4-Bis(3-methoxyphenyl)-2,4-dimethyl-1,3-dioxa-5-thiazatriquinane 
(35b):  
HR-MS (ESI): m/z Calcd for C22H25NNaO4S [M+Na]+: 422.1402. Found: 422.1407. 
IR (film, cm-1): 2995, 2932, 2834, 1602, 1583, 1486. 
1H NMR (400 MHz, CDCl3): 1.73 (s, 3H), 1.73 (s, 3H), 3.10 (dd, J = 12.8, 3.0 Hz, 1H), 3.16 (d, J = 
12.8 Hz, 1H), 3.83 (s, 3H), 3.84 (s, 3H), 5.12 (s, 1H), 5.19 (d, J = 3.0 Hz, 1H), 5.44 (s, 1H), 6.82 – 6.84 
(m, 1H), 6.85 (ddd, J = 2.4, 0.8, 0.8 Hz, 1H), 7.00 (d, J = 7.5 Hz, 1H), 7.02 – 7.06 (m, 2H), 7.08 (dd, J 
= 2.4, 1.8 Hz, 1H), 7.27 (dd, J = 7.5, 7.5 Hz, 1H), 7.32 (dd, J = 8.5, 8.5 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ 24.4, 25.9, 38.4, 55.1, 55.3, 82.8, 85.7, 86.7, 98.4, 100.6, 110.7, 111.3, 
112.3, 112.6, 117.0, 117.6, 129.1, 129.6, 144.8, 145.0, 159.2, 159.8. 
 
rac-(2R,2aS,4S,4aS,6aS)-2,4-Bis(3-methoxyphenyl)-2,4-dimethyl-1,3-dioxa-5-thiazatriquinane 
(35c): 
HR-MS (ESI): m/z Calcd for C22H25NNaO4S [M+Na]+: 422.1402. Found: 422.1401. 
IR (film, cm-1): 2991, 2936, 2835, 1600, 1584, 1488. 
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1H NMR (400 MHz, CDCl3): δ 1.51 (s, 3H), 1.58 (s, 3H), 3.31 (dd, J = 12.6, 3.0 Hz, 1H), 3.39 (d, J = 
12.6 Hz, 1H), 3.79 (s, 3H), 3.86 (s, 3H), 4.82 (s, 1H), 5.36 (d, J = 3.0 Hz, 1H), 5.41 (s, 1H), 6.80 (ddd, 
J = 8.2, 2.5, 1.0 Hz, 1H), 6.84 – 6.88 (m, 2H), 6.90 (ddd, J = 7.7, 1.6, 1.0 Hz, 1H), 7.12 (ddd, J = 8.9, 
1.6, 1.0 Hz, 1H), 7.23 – 7.33 (m, 3H). 
13C NMR (100 MHz, CDCl3): δ 22.8, 27.0, 38.3, 55.2, 55.3, 81.7, 85.1, 86.5, 97.7, 100.4, 111.0, 112.3, 
112.5, 112.9, 117.0, 118.4, 128.5, 129.7, 142.3, 145.5, 159.0, 159.8.  
 
rac-(2R,2aS,4R,4aS,6aS)-2,4-Bis(3-methoxyphenyl)-2,4-dimethyl-1,3-dioxa-5-thiazatriquinane 
(35d): 
HR–MS (ESI): m/z Calcd for C22H25NNaO4S [M+Na]+: 422.1402. Found: 422.1412. 
IR (film, cm-1): 2998, 2933, 2834, 1601, 1583, 1485. 
1H NMR (400 MHz, CDCl3): δ 1.62 (s, 3H), 1.70 (s, 3H), 3.19 – 3.24 (m, 2H), 3.64 (s, 3H), 3.76 (s, 
3H), 5.11 (s, 1H), 5.15 (s, 1H), 5.41 – 5.46 (m, 1H), 6.61 (dd, J = 2.6, 1.6 Hz, 1H), 6.65 (ddd, J = 7.6, 
1.6, 1.0 Hz, 1H), 6.74 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 6.85 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 7.11 – 7.16 
(m, 2H), 7.24 – 7.32 (m, 2H). 
13C NMR (100 MHz, CDCl3): δ 22.2, 25.5, 38.6, 54.9, 55.0, 82.9, 85.0, 86.9, 98.0, 101.0, 109.7, 112.3, 
113.0, 113.6, 116.9, 118.3, 128.5, 128.7, 142.4, 144.8, 159.0 (×2). 
 
 
The relative configurations of 35a–d were determined by NOESY spectra. The chemical shifts of 
protons were shown in the parentheses. 
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rac-(2S,2aS,4R,4aS,6aS)-3,3’-(2,4-Dimethyl-1,3-dioxa-5-thiazatriquinane-2,4-diyl)bisphenol 
(36b) 
 
Under Ar atmosphere, to a solution of 1-propanethiol (171 µL, 1.89 mmol) in DMF (5.0 mL) was added 
tBuOK (199 mg, 1.77 mmol) and stirred at 130 °C. After stirring for 2 h, a solution of 35b (47 mg, 1.89 
mmol) in DMF (1.0 mL) was added to the mixture at rt and stirred at 130 °C for 8 h. The resulting 
mixture was poured into saturated NH4Cl aqueous solution (5 mL) and extracted with CHCl3 (10 mL, 5 
mL × 2). The combined organic layers were dried over anhydrous Na2SO4. After removing the solvent 
in vacuo, the residue was purified by preparative TLC (Hexane:EtOAc = 2:1) to afford 36b (27.0 mg, 
62%) as a colorless oil. 
36b 
HR-MS (ESI): m/z Calcd for C20H21NNaO4S [M+Na]+: 394.1089. Found: 394.1075. 
IR (KBr, cm-1): 3410, 2931, 1589, 1490, 1449. 
1H NMR (400 MHz, CD3OD): δ 1.65 (s, 3H), 1.68 (s, 3H), 3.04 – 3.13 (m, 2H), 5.13 (s, 1H), 5.18 (dd, 
J = 2.3, 1.3 Hz, 1H), 5.43 (s, 1H), 6.67 – 6.75 (m, 2H), 6.85 – 6.94 (m, 3H), 6.98 (dd, J = 1.9 , 1.9 Hz, 
1H), 7.14 (dd, J = 7.8, 7.8 Hz, 1H), 7.22 (dd, J = 7.8, 7.8 Hz, 1H). The OH peak/signal was not observed. 
13C NMR (100 MHz, CD3OD): δ 24.9, 26.1, 38.7, 83.6, 87.0, 88.0, 99.7, 101.8, 113.0, 113.1, 115.2, 
115.3, 117.2, 117.3, 130.0, 130.8, 146.0, 146.5, 158.0, 158.8. 
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General procedure for salt formation with camphorsulfonic acid  
 
rac-(2S,2aS,4R,4aS,6aS)-3,3’-(2,4-Dimethyl-1,3-dioxa-5-thiazatriquinane-2,4-diyl)bisphenol 
camphorsulfonate (36b·CSA) 
36b (10 mg, 0.027 mmol) was dissolved in EtOAc (1 mL), and 0.1 M solution of CSA in EtOAc (1.0 
eq.) was added. The precipitate was collected by filtration and dried in vacuo to afford 36b·CSA (12 
mg, 76%) as a white solid. 
36b·CSA 
Mp (dec.): 203–206 °C 
Anal Calcd for C20H21NO4S·C10H16O4S·0.5H2O: C, 58.80; H, 6.25; N, 2.29. Found: C, 58.78; H, 6.40; 
N, 2.35. 
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Synthesis of 1-oxa-3,5-dithiazatriquinane derivatives 
 
(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-2’(methanethiol)-3-methoxy-
spiro[molphinan-6,5’-2’,5-dihydrooxazole]-14-ol (42) 
 
Under Ar atmosphere, naltrexone methyl ether (9, 1.36 g, 3.81 mmol), p-toluenesulfonylmethyl 
isocyanide (3.72 g, 19.1 mmol), and K2CO3 (2.63 g, 19.1 mmol) were suspended in MeOH (20 mL) and 
stirred at rt for 3 h. After concentration of reaction mixture, the residue was poured into distilled water 
(20 mL) and extracted with CHCl3 (20 mL, 10 mL × 2). The combined organic layers were washed with 
brine (10 mL), dried over anhydrous Na2SO4 and evaporated in vacuo. The crude product was resolved 
in THF (10 mL). To the solution was added 2 M HCl aqueous solution (16 mL) and stirred at 60 °C for 
1 h. The reaction mixture was neutralized with K2CO3 to pH 9 and extracted with CHCl3 (20 mL, 10 
mL × 2). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na 2SO4 
and evaporated in vacuo. The obtained crude product was used in next reaction without further 
purification. 
Under Ar atmosphere, the crude product, NH4Cl (1.63 g, 30.5 mmol), NaOAc (5.00 g, 61.0 mmol), and 
2,4-dihydroxy-1,3-dithiane (2.32 g, 15.24 mmol) were suspended in MeOH (20 mL) at rt with stirring 
for 5 h. The reaction mixture was poured into saturated NaHCO3 aqueous solution (20 mL), and 
extracted with CHCl3 (20 mL × 2, 10 mL). The combined organic layers were washed with brine (15 
mL), dried over anhydrous Na2SO4, and then evaporated in vacuo. The residue was purified by silica 
gel column chromatography (CHCl3:MeOH:NH3 aqueous = 100:1:0.1 to 50:1:0.1 to 30:1:0.1) to afford 
methylthio oxazoline (R)-42 (0.406 g, 24% from 6) and (S)-42 (0.379 g, 22% from 9) as white 
amorphous materials. 
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(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-2’(methanethiol)-3-methoxy-spiro[(2’R,5’S)-
molphinan-6,5’-2’,5-dihydrooxazole]-14-ol ((R)-42): 
HR-MS (ESI): m/z Calcd for C24H31N2O4S [M+H]+: 443.2005. Found: 443.2009. 
IR (film, cm-1): 3376, 3001, 2926, 2832, 1644, 1610, 1504. 
1H NMR (400 MHz, CDCl3): δ 0.07 – 0.17 (m, 2H), 0.46 – 0.56 (m, 2H), 0.78 – 0.92 (m, 1H), 1.38 – 
1.46 (m, 2H), 1.64 (td, J = 13.6, 2.8 Hz, 1H), 1.77 (dt, J = 13.6, 2.8 Hz, 1H), 1.99 (tt, J = 13.6, 2.8 Hz, 
1H), 2.16 (td, J = 12.0, 4.0 Hz, 1H), 2.29 (td, J = 12.5, 5.1 Hz, 1H), 2.34 – 2.45 (m, 2H), 2.61 (dd, J = 
18.4, 5.6 Hz, 1H), 2.66 (dd, J = 12.0, 4.0 Hz, 1H), 2.91 (d, J = 2.0 Hz, 1H), 3.03 (d, J = 18.4 Hz, 1H), 
3.09 (d, J = 4.7 Hz, 1H), 3.86 (s, 3H), 3.91 – 4.02 (m, 2H), 4.81 (s, 1H), 5.82 (ddd, J = 5.3, 4.5, 2.4 Hz, 
1H), 6.61 (d, J = 8.2 Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 7.63 (ddd, J = 2.4, 1.2, 0.8 Hz, 1H). The OH 
peak/signal was not observed. 
13C NMR (100 MHz, CDCl3): δ 3.92, 3.94, 9.5, 22.7, 26.2, 26.8, 32.1, 44.0, 44.5, 46.9, 56.4, 59.2, 62.7, 
70.1, 75.4, 89.0, 93.8, 113.5, 118.7, 124.9, 131.8, 141.8, 145.2, 161.8.  
 
(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-2’(methanethiol)-3-methoxy-spiro[(2’S,5’S)-
molphinan-6,5’-2’,5-dihydrooxazole]-14-ol ((S)-42): 
HR-MS (ESI): m/z Calcd for C24H31N2O4S [M+H]+: 443.2005. Found: 443.1992. 
IR (film, cm-1): 3375, 3001, 2926, 2832, 1644, 1610, 1504. 
1H NMR (400 MHz, CDCl3): δ 0.06 – 0.20 (m, 2H), 0.45 – 0.61 (m, 2H), 0.77 – 0.92 (m, 1H), 1.43 (dt, 
J = 12.0, 3.4 Hz, 1H), 1.47 (dd, J = 12.0, 3.2Hz, 1H), 1.61 (dt, J = 13.8, 3.4 Hz, 1H), 1.64 (dt, J = 12.0, 
3.4 Hz, 1H), 2.16 (td, J = 12.0, 3.2 Hz, 1H), 2.21 (dt, J = 13.8, 3.4 Hz, 1H), 2.28 (td, J = 12.0, 4.8 Hz, 
1H), 2.32 – 2.44 (m, 2H), 2.61 (dd, J = 18.4, 5.6 Hz, 1H), 2.65 (dd, J = 12.0, 4.8 Hz, 1H), 3.03 (d, J = 
18.4 Hz, 1H), 3.09 (d, J = 5.6 Hz, 1H), 3.86 (s, 3H), 3.93 – 3.96 (m, 2H), 4.72 (s, 1H), 5.89 (td, J = 4.4, 
2.4 Hz, 1H), 6.61 (d, J = 8.2 Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 7.68 (dt, J = 2.4, 1.2 Hz, 1H). The OH 
and SH peaks/signals were not observed. 
13C NMR (100 MHz, CDCl3): δ 3.9, 4.0, 9.5, 22.6, 26.3, 27.9, 32.3, 44.1, 44.3, 47.0, 56.6, 59.2, 62.6, 
70.1, 74.8, 90.5, 94.1, 113.9, 118.8, 125.0, 131.7, 141.9, 145.2, 162.6. 
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(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-3-methoxy-spiro[(2’S,2a’R,4a’R,6a’R)-
molphinan-6,2’-1’,3’-dioxa-5’-thiazatriquinane]-14-ol ((R)-43) 
 
Under Ar atmosphere, (R)-42 (62.8 mg, 0.142 mmol), glycolaldehyde dimer (51.1 mg, 11.0 mmol), and 
CSA (99.3 mg, 0.426 mmol) in CHCl3 (5 ml) was stirred at rt for 2 h. The reaction mixture was poured 
into saturated NaHCO3 aqueous solution (10 mL) and extracted with CHCl3 (10 mL, 5 mL, 3 mL). The 
combined organic layers were washed with brine (3 mL), dried over anhydrous Na 2SO4, and then 
evaporated in vacuo. The residue was purified by preparative TLC (CHCl 3:MeOH:NH3 aqueous = 
30:1:0.1) to afford (R)-43 (38.2 mg, 55%) as a colorless amorphous material. 
(R)-43 
HR-MS (ESI): m/z Calcd for C26H32N2NaO5S [M+Na]+: 507.1930. Found: 507.1943. 
IR (film, cm-1): 3373, 3000, 2927, 2832, 1636, 1608, 1500, 1441. 
1H NMR (400 MHz, CDCl3): δ 0.06 – 0.19 (m, 2H), 0.46 – 0.61 (m, 2H), 0.77 – 0.91 (m, 1H), 1.50 – 
1.62 (m, 3H), 1.71 (dt, J = 14.2, 5.3 Hz, 1H), 1.96 (ddd, J = 14.2, 8.3, 6.0 Hz, 1H), 2.18 (td, J = 12.0, 
3.6 Hz, 1H), 2.29 (td, J = 12.0, 4.4 Hz, 1H), 2.34 – 2.42 (m, 2H), 2.60 (dd, J = 18.4, 6.2 Hz, 1H), 2.66 
(dd, J = 12.0, 4.4 Hz, 1H), 3.03 (d, J = 18.4 Hz, 1H), 3.10 (d, J = 6.2 Hz, 1H), 3.12 (dd, J = 12.2, 3.4 
Hz, 1H), 3.26 (dd, J = 12.2, 3.4 Hz, 1H), 3.81 (dd, J = 9.6, 3.6 Hz, 1H), 3.92 (s, 3H), 4.01 (dd, J = 9.6, 
1.2 Hz, 1H), 4.80 (s, 1H), 4.88 (s, 1H), 4.98 (dd, J = 3.6, 1.2 Hz, 1H), 5.12 (t, J = 3.4 Hz, 1H), 6.56 (d, 
J = 8.2 Hz, 1H), 6.70 (d, J = 8.2 Hz, 1H). The OH peak/signal was not observed. 
13C NMR (100 MHz, CDCl3): δ 3.9, 4.1, 9.5, 22.6, 25.9, 27.6, 32.1, 36.9, 44.0, 47.8, 57.3, 59.4, 62.4, 
69.7, 71.8, 78.8, 86.2, 89.7, 94.4, 100.9, 115.2, 118.2, 125.1, 131.1, 141.9, 146.9.  
 
The relative configurations of (R)-43 were determined by NOESY spectra. The chemical shifts  of 
protons were shown in the parentheses. 
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5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-spiro[(2’S,2a’R,4a’R,6a’R)-molphinan-6,2’-
1’,3’-dioxa-5’-thiazatriquinane]-3,14-diol ((R)-44) 
 
Under an Ar atmosphere, to a solution of 1-propaneethiol (160 µL, 1.44 mmol) in DMF (3.0 mL) was 
added tBuOK (121.2 mg, 1.08 mmol) and stirred at 130 °C. After stirring for 2 h, a solution of (R)-43 
(34.5 mg, 0.072 mmol) in DMF (1.0 mL) was added to the mixture at rt  and stirred at 130 °C for 8 h. 
The resulting mixture was poured into saturated NH4Cl aqueous solution (5 mL), extracted with CHCl3 
(10 mL, 5 mL × 2). The combined organic layers were dried over anhydrous Na2SO4. After removing 
the solvent in vacuo, the residue was purified by preparative TLC (CHCl3:MeOH:NH3 aqueous = 
10:1:0.1) to afford (R)-44 (28.0 mg, 83%) as a colorless oil. 
(R)-44 
HR-MS (ESI): m/z Calcd for C25H31N2O5S [M+H]+: 471.1954. Found: 471.1956. 
IR (film, cm-1): 3387, 3000, 2925, 2836, 1640, 1616, 1509, 1461. 
1H NMR (400 MHz, CDCl3): δ 0.08 – 0.16 (m, 2H), 0.47 – 0.56 (m, 2H), 0.79 – 0.88 (m, 1H), 1.43 – 
1.57 (m, 3H), 1.72 (dt, J = 14.6, 4.2 Hz, 1H), 1.94 (ddd, J = 14.3, 11.0, 4.2 Hz, 1H), 2.15 – 2.29 (m, 
2H), 2.33 – 2.39 (m, 2H), 2,56 (dd, J = 18.3, 6.0 Hz, 1H), 2.65 (d, J = 8.7 Hz, 1H), 2.99 (d, J = 18.3 
Hz, 1H), 3.05 – 3.12 (m, 1H), 3.23 (dd, J = 12.4, 4.0 Hz, 1H), 3.37 (dd, J = 12.4, 1.8 Hz, 1H), 3.69 (dd, 
J = 10.0, 3.2 Hz, 1H), 3.96 (d, J = 10.0 Hz, 1H), 4.72 (s, 1H), 4.85 (s, 1H), 4.92 (d, J = 3.2 Hz, 1H), 
5.06 (dd, J = 4.0, 1.8 Hz, 1H), 6.52 (d, J = 8.2 Hz, 1H), 6.70 (d, J = 8.2 Hz, 1H). The OH peaks/signals 
were not observed. 
13C NMR (100 MHz, CDCl3): δ 3.9, 4.1, 9.5, 22.7, 27.1, 27.4, 31.7, 36.8, 44.2, 48.0, 59.3, 62.4, 69.9, 
72.1, 80.2, 85.6, 89.8, 94.3, 101.0, 117.2, 118.8, 123.8, 130.4, 138.3, 145.6.  
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(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-spiro[(2’S,2a’R,4a’R,6a’R)-molphinan-6,2’-
1’,3’-dioxa-5’-thiazatriquinane]-3,14-diol camphorsulfonate ((R)-44·CSA) 
According to the general procedure for salt formation, (R)-44·CSA was prepared from trimer (R)-44 
(12 mg, 0.026 mmol) to give a white solid (14 mg, 77%).  
(R)-44·CSA 
Mp (dec.): 212–215 °C 
Anal Calcd for C25H30N2O5S·C10H16O4S·3.0H2O: C, 55.54; H, 6.92; N, 3.70. Found: C, 55.54; H, 6.67; 
N, 3.46. 
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(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-3-methoxy-spiro[(2’S,2a’S,4a’S,6a’S)-
molphinan-6,2’-1’,3’-dioxa-5’-thiazatriquinane]-14-ol ((S)-43) 
 
According to the procedure used to synthesize (R)-43, (S)-43 was synthesized from (S)-42 (30 mg, 
0.067 mmol) to give a colorless amorphous material (19 mg, 57%). 
(S)-43 
HR-MS (ESI): m/z Calcd for C26H33N2O5S [M+H]+: 485.2110. Found: 485.2125. 
IR (film, cm-1): 3365, 3000, 2928, 2833, 1637, 1610, 1504, 1450. 
1H NMR (400 MHz, CDCl3): δ 0.06 – 0.20 (m, 2H), 0.45 – 0.61 (m, 2H), 0.77 – 0.93 (m, 1H), 1.52 (dd, 
J = 13.0, 2.4 Hz, 1H), 1.55 – 1.82 (m, 3H), 1.99 (dt, J = 13.2, 6.4 Hz, 1H), 2.17 (td, J = 12.4, 2.8 Hz, 
1H), 2.25 (td, J = 12.4, 4.0 Hz, 1H), 2.31 – 2.42 (m, 2H), 2.60 – 2.69 (m, 2H), 3.03 (d, J = 18.4 Hz, 
1H), 3.12 (d, J = 5.6 Hz, 1H), 3.25 (d, J = 12.6 Hz, 1H), 3.29 (dd, J = 12.6, 2.8 Hz, 1H), 3.65 (dd, J = 
10.0, 3.6 Hz, 1H), 3.85 (s, 3H), 3.96 (d, J = 10.0 Hz, 1H), 4.63 (s, 1H), 5.04 (d, J = 2.8 Hz, 1H), 5.34 
(s, 1H), 5.39 (d, J = 3.6 Hz, 1H), 6.61 (d, J = 8.2 Hz, 1H), 6.73 (d, J = 8.2 Hz, 1H). The OH peak/signal 
was not observed. 
13C NMR (100 MHz, CDCl3): δ 3.9, 4.2, 9.5, 22.5, 25.8, 28.8, 32.7, 37.9, 43.9, 47.9, 56.6, 59.4, 62.5, 
69.5, 71.4, 80.9, 85.9, 92.8, 97.0, 100.4, 113.8, 118.6, 125.5, 131.2, 142.1, 146.2. 
 
The relative configurations of (S)-43 were determined by NOESY spectra. The chemical shifts of 
protons were shown in the parentheses. 
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(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-spiro[(2’S,2a’S,4a’S,6a’S)-molphinan-6,2’-
1’,3’-dioxa-5’-thiazatriquinane]-3,14-diol ((S)-44) 
 
According to the procedure used to synthesize (R)-44, (S)-44 was synthesized from (S)-43 (19 mg, 
0.038 mmol) to give a colorless amorphous material (14 mg, 77%). 
(S)-44 
HR-MS (ESI): m/z Calcd for C25H31N2O5S [M+H]+: 471.1954. Found: 471.1958. 
IR (film, cm-1): 3387, 3000, 2925, 2836, 1640, 1616, 1509, 1462. 
1H NMR (400 MHz, CDCl3): δ 0.06 – 0.16 (m, 2H), 0.49 – 0.56 (m, 2H), 0.78 – 0.86 (m, 1H), 1.47 (d, 
J = 11.0 Hz, 1H), 1.58 – 1.80 (m, 3H), 1.97 (ddd, J = 14.8, 8.0, 8.0 Hz, 1H), 2.15 – 2.29 (m, 2H), 2.30 
– 2.40 (m, 2H), 2.57 – 2.66 (m, 2H), 3.01 (d, J = 18.8 Hz, 1H), 3.11 (d, J = 6.0 Hz, 1H), 3.27 (d, J = 
12.8 Hz, 1H), 3.31 (dd, J = 12.8, 3.2 Hz, 1H), 3.69 (dd, J = 10.0, 3.6 Hz, 1H), 3.97 (d, J = 10.0 Hz, 1H), 
4.65 (s, 1H), 5.06 (d, J = 2.8 Hz, 1H), 5.39 (d, J = 3.6 Hz, 1H), 5.41 (s, 1H), 6.56 (d, J = 8.2 Hz, 1H), 
6.71 (d, J = 8.2 Hz, 1H). The OH peaks/signals were not observed. 
13C NMR (100 MHz, CDCl3): δ 3.8, 4.2, 9.5, 22.6, 25.7, 28.8, 33.0, 37.9, 43.8, 48.2, 59.4, 62.4, 69.5, 
71.5, 80.5, 86.2, 92.7, 96.7, 100.3, 117.6, 119.1, 125.0, 130.9, 137.7, 144.6.  
 
(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-spiro[(2’S,2a’S,4a’S,6a’S)-molphinan-6,2’-
1’,3’-dioxa-5’-thiazatriquinane]-3,14-diol camphorsulfonate ((S)-44·CSA) 
According to the general procedure for salt formation, (S)-44·CSA was prepared from trimer (S)-44 (14 
mg, 0.029 mmol) to give a white solid (18 mg, 86%). 
(S)-44·CSA 
Mp (dec.): 208–212 °C 
Anal Calcd for C25H30N2O5S·C10H16O4S·3.0H2O: C, 55.54; H, 6.92; N, 3.70. Found: C, 55.71; H, 6.64; 
N, 3.41. 
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(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-3-methoxy-spiro[(2’S,2a’R,4a’R,6a’R)-
molphinan-6,2’-1’-oxa-3’,5’-dithiazatriquinane]-14-ol ((R)-41) 
 
Under Ar atmosphere, (R)-42 (84 mg, 0.190 mmol), 2,4-dihydroxy-1,3-dithiane (87 mg, 0.570 mmol), 
and CSA (265 mg, 1.14 mmol) in CHCl3 (5 ml) was stirred at rt for 2 h. The reaction mixture was poured 
into saturated NaHCO3 aqueous solution (10 mL) and extracted with CHCl3 (10 mL, 10 mL, 5 mL). The 
combined organic layers were washed with brine (3 mL), dried over anhydrous Na2SO4, and then 
evaporated in vacuo. The residue was purified by preparative TLC (CHCl 3:MeOH:NH3 aqueous = 
30:1:0.1) to afford (R)-41 (42 mg, 50%) as a colorless amorphous material. 
(R)-41 
HR-MS (ESI): m/z Calcd for C26H33N2O4S2 [M+H]+: 501.1882. Found: 501.1899. 
IR (film, cm-1):3374, 2999, 2926, 2832, 1636, 1610,1503, 1447. 
1H NMR (400 MHz, CDCl3): δ 0.06 – 0.20 (m, 2H), 0.46 – 0.60 (m, 2H), 0.79 – 0.91 (m, 1H), 1.46 – 
1.63 (m, 3H), 1.75 (dt, J = 14.4, 4.5 Hz, 1H), 1.95 (ddd, J = 14.4, 10.4, 4.4 Hz, 1H), 2.18 (td, J = 12.0, 
3.6 Hz, 1H), 2.29 (dd, J = 12.4, 4.8 Hz, 1H), 2.32 – 2.43 (m, 2H), 2.60 (dd, J = 18.6, 6.2 Hz, 1H), 2.66 
(dd, J = 12.0, 4.8 Hz, 1H), 2.95 – 3.16 (m, 6H), 3.87 (s, 3H), 4.65 (s, 1H), 4.70 (t, J = 6.2 Hz, 1H), 4.90 
(s, 1H), 5.13 (t, J = 5.2 Hz, 1H), 6.57 (d, J = 8.2 Hz, 1H), 6.69 (d, J = 8.2 Hz, 1H). The OH peak/signal 
was not observed. 
13C NMR (100 MHz, CDCl3): δ 3.9, 4.1, 9.5, 22.7, 27.41, 27.48, 31.9, 34.9, 39.7, 44.2, 47.6, 56.9, 59.4, 
62.5, 69.8, 73.8, 78.6, 88.2, 89.9, 98.9, 114.2, 118.1, 125.0, 131.2, 142.1, 147.0.  
 
The relative configurations of (R)-41 were determined by NOESY spectra. The chemical shifts of 
protons were shown in the parentheses. 
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(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-spiro[(2’S,2a’R,4a’R,6a’R)-molphinan-6,2’-
1’-oxa-3’,5’-dithiazatriquinane]-3,14-diol ((R)-45) 
 
According to the procedure used to synthesize (R)-44, (R)-45 was synthesized from (R)-41 (36 mg, 
0.073 mmol) to give a colorless amorphous material (28 mg, 80%).  
(R)-45 
HR-MS (ESI): m/z Calcd for C25H31N2O4S2 [M+H]+: 487.1725. Found: 487.1711.  
IR (film, cm-1): 3348, 3001, 2927, 2831, 1641, 1621, 1504, 1458. 
1H NMR (400 MHz, CDCl3): δ 0.07 – 0.18 (m, 2H), 0.56 – 0.62 (m, 2H), 0.78 – 0.90 (m, 1H), 1.45 (ddd, 
J = ,13.7, 4.1, 4.1 Hz, 1H), 1.49 – 1.58 (m, 2H), 1.69 (ddd, J = 14.2, 4.1, 4.1 Hz, 1H),1.90 (ddd, J = 
14.2, 11.5, 4.1 Hz, 1H), 2.19 (ddd, J =3.6, 11.9, 11.9 Hz, 1H), 2.28 (ddd, J = 12.0, 12.0, 5.0 Hz, 1H), 
2.33 – 2.41 (m, 2H), 2.57 (dd, J = 18.2, 6.0 Hz, 1H), 2.66 (dd, J = 10.0, 4.1 Hz, 1H), 2.99 (d, J = 18.4 
Hz, 1H), 3.07 – 3.12 (m, 2H), 3.20 (dd, J = 5.0, 5.0 Hz, 1H), 3.23 (dd, J = 5.0, 5.0 Hz, 1H), 3.31 (dd, J 
= 11.7, 5.4 Hz, 1H), 4.66 (s, 1H), 4.90 (s, 1H), 4.95 (dd, J = 5.4, 5.4 Hz, 1H), 4.98 (dd, J = 5.0, 2.3 Hz, 
1H), 6.52 (d, J = 8.2 Hz, 1H), 6.68 (d, J = 8.2 Hz, 1H). The OH peaks/signals were not observed. 
13C NMR (100 MHz, CDCl3): δ 3.9, 4.1, 9.4, 22.7, 27.4, 31.5, 38.0, 38.6, 44.3, 47.9, 59.2, 62.3, 69.9, 
75.2, 80.0, 85.8, 90.2, 96.8, 117.1, 118.7, 124.0, 130.6, 138.1, 145.7.  
 
(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-spiro[(2’S,2a’R,4a’R,6a’R)-molphinan-6,2’-
1’-oxa-3’,5’-dithiazatriquinane]-3,14-diol camphorsulfonate ((R)-45·CSA) 
According to the general procedure for salt formation, (R)-45·CSA was prepared from trimer (R)-45 
(17 mg, 0.035 mmol) to give a white solid (17 mg, 68%).  
(R)-45·CSA  
Mp (dec.): 216–220 °C 
Anal Calcd for C25H30N2O4S2·C10H16O4S·2.3H2O: C, 55.29; H, 6.71; N, 3.68. Found: C, 55.17; H, 6.44; 
N, 3.56. 
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(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-3-methoxy-spiro[(2’S,2a’S,4a’S,6a’S)-
molphinan-6,2’-1’-oxa-3’,5’-dithiazatriquinane]-14-ol ((S)-41) 
 
According to the procedure used to synthesize (R)-41, (S)-41 was synthesized from (S)-42 (61 mg, 
0.138 mmol) to give a colorless amorphous material (33 mg, 48%).  
(S)-41 
HR-MS (ESI): m/z Calcd for C26H33N2O4S2 [M+H]+: 501.1882. Found: 501.1880. 
IR (film, cm-1): 3365, 2999, 2927, 2832, 1637, 1611, 1503, 1449. 
1H NMR (400 MHz, CDCl3): δ 0.08 – 0.17 (m, 2H), 0.48 – 0.59 (m, 2H), 0.78 – 0.90 (m, 1H), 1.48 – 
1.63 (m, 2H), 1.68 (dt, J = 13.6, 5.4 Hz, 1H), 1.79 (dt, J = 13.6, 6.0 Hz, 1H), 2.07 (ddd, J = 13.6, 8.4, 
5.4 Hz, 1H), 2.18 (td, J = 12.4, 4.0 Hz, 1H), 2.24 (td, J = 12.4, 4.0 Hz, 1H), 2.36 (t, J = 6.0 Hz, 2H), 
2.59 – 2.67 (m, 2H), 2.96 – 3.08 (m, 3H), 3.09 – 3.15 (m, 2H), 3.41 (dd, J = 12.2, 5.2 Hz, 1H), 3.85 (s, 
3H), 4.60 (s, 1H), 4.93 (dd, J = 5.2, 3.0 Hz, 1H), 5.13 (s, 1H), 5.47 (dd, J = 4.6, 3.7 Hz, 1H), 6.60 (d, J 
= 8.2 Hz, 1H), 6.73 (d, J = 8.2 Hz, 1H). The OH peak/signal was not observed. 
13C NMR (100 MHz, CDCl3): δ 3.87, 4.14, 9.48, 22.6, 26.5, 28.5, 32.6, 38.0, 40.1, 43.9, 47.8, 56.6, 
59.4, 62.4, 69.6, 74.7, 81.0, 86.7, 93.2, 100.5, 113.7, 118.5, 125.4, 131.2, 142.1, 146.3.  
 
The relative configurations of (S)-41 were determined by NOESY spectra. The chemical shifts of 
protons were shown in the parentheses. 
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(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-spiro[(2’S,2a’S,4a’S,6a’S)-molphinan-6,2’-
1’-oxa-3’,5’-dithiazatriquinane]-3,14-diol ((S)-45) 
 
According to the procedure used to synthesize (R)-44, (S)-45 was synthesized from (S)-41 (39 mg, 
0.078 mmol) to give a colorless amorphous material (28 mg, 77%).  
(S)-45 
HR-MS (ESI): m/z Calcd for C25H31N2O4S2 [M+H]+: 487.1725. Found: 487.1731. 
IR (film, cm-1): 3348, 3001, 2927, 2831, 1641, 1621, 1504, 1458. 
1H NMR (400 MHz, CDCl3): δ 0.05 – 0.18 (m, 2H), 0.47 – 0.58 (m, 2H), 0.79 – 0.88 (m, 1H), 1.46 (d, 
J = 9.16 Hz, 1H), 1.58 – 1.72 (m, 2H), 1.80 (ddd, J = 6.0, 6.0, 14.0 Hz, 1H), 2.08 (ddd, J = 5.5, 8.2, 
13.6 Hz, 1H), 2.15 – 2.27 (m, 2H), 2.30 – 2.40 (m, 2H), 2.56 – 2.65 (m, 2H), 2.98 – 3.12 (m, 4H), 3.15 
(dd, J = 2.8, 12.4 Hz, 1H), 3.45 (dd, J = 5.3, 12.4 Hz, 1H), 4.62 (s, 1H), 4.92 (dd, 2.8, 5.0 Hz, 1H), 5.19 
(s, 1H), 5.44 (dd, J = 4.6, 4.6 Hz, 1H), 6.55 (d, J = 7.8 Hz, 1H), 6.72 (d, J = 7.8 Hz, 1H). The OH 
peaks/signals were not observed. 
13C NMR (100 MHz, CDCl3): δ 3.9, 4.1, 9.5, 22.6, 26.6, 28.4, 32.7, 37.9, 40.9, 43.9, 48.0, 59.4, 62.4, 
69.6, 74.0, 80.6, 87.3, 93.0, 100.6, 117.5, 119.0, 124.6, 130.8, 137.8, 144.7. 
 
(5R,9R,13S,14S)-17-(Cyclopropylmethyl)-4,5-epoxy-spiro[(2’S,2a’S,4a’S,6a’S)-molphinan-6,2’-
1’-oxa-3’,5’-dithiazatriquinane]-3,14-diol camphorsulfonate ((S)-45·CSA) 
According to the general procedure for salt formation, (S)-45·CSA was prepared from trimer (S)-45 (14 
mg, 0.029 mmol) to give a white solid (17 mg, 82%). 
(S)-45·CSA 
Mp (dec.): 210–212 °C 
Anal Calcd for C25H30N2O4S2·C10H16O4S·2.1H2O: C, 55.55; H, 6.69; N, 3.70. Found: C, 55.83; H, 6.46; 
N, 3.40. 
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Chapter 3 
 
General procedure A 
7-(3-Methoxyphenyl)-2,4,6,8,9-pentathia-1,3,5-triphosphaadamantane-1,3,5-trisulfide (53) 
 
Under Ar atmosphere, 3’-methoxyacetophenone 32 (338 mg, 2.25 mmol) and P4S10 (22.5 mmol) were 
suspended in benzene (12 mL) and stirred at refluxing temperature for 20 h. The reaction mixture was 
filtered through an 11G-4 glass filter and washed with CHCl3 (80 mL). The filtrate was evaporated in 
vacuo and then the residue was filtered through a silica gel column chromatography (CHCl3). The eluate 
was evaporated in vacuo and then the residue was purified by recrystallization from hexane/CHCl 3 to 
give 53 as a crystal material (419 mg, 39%). 
53 
HR-MS (ESI): m/z Calcd for C9H10OP3S8 [M+H]+: 482.7710, found: 482.7728. 
IR (KBr, cm-1): 2922, 2869, 2830, 1460, 785, 691, 533. 
1H NMR (400 MHz, CDCl3): δ 3.12 (d, 2JHP = 10.8 Hz, 2H), 3.87 (s, 3H), 7.08 (dd, J = 8.2, 2.2 Hz, 1H), 
7.14 (dd, J = 2.2, 2.2 Hz, 1H), 7.20 (dd, J = 8.2, 2.2 Hz, 1H), 7.49 (dd, J = 8.2, 8.2 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ 42.9 (d, 1JCP = 53.4 Hz), 55.9, 111.7, 117.0, 117,1, 131.7, 141.8, 161.2, 
The quaternary carbon peak was not observed. 
31P NMR (160 MHz, CDCl3) δ 56.7, 62.0. 
Anal Cacld for C9H9OP3S8: C, 22.40; H, 1.88. Found: C, 22.27; H, 1.99. 
Mp (dec.): 181.1–181.7 °C 
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General procedure B 
7-Phenyl-2,4,6,8,9-pentathia-1,3,5-triphosphaadamantane-1,3,5-trisulfide (55a) 
 
Under Ar atmosphere, acetophenone 54a (103 mg, 0.860 mmol) and P4S10 (8.60 mmol) were suspended 
in benzene (5 mL) and stirred at refluxing temperature for 20 h. The reaction mixture was filtered 
through an 11G-4 glass filter and washed with CHCl3 (80 mL). The filtrate was evaporated in vacuo, 
and then the residue was purified by recrystallization from hexane/CHCl3 to give 55a as a colorless 
crystal (179 mg, 46%). 
55a 
HR-MS (ESI): m/z Calcd for C8H8P3S8 [M+H]+: 452.7605, found: 452.7593. 
IR (KBr, cm-1): 2920, 2873, 1459, 758, 710, 687, 532. 
1H NMR (400 MHz, CDCl3): δ 3.14 (d, 2JHP = 11.2 Hz, 2H), 7.57 – 7.61 (m, 3H), 7.62 – 7.67 (m, 2H). 
13C NMR (100 MHz, CDCl3): δ 42.8 (d, 1JCP = 53.4 Hz), 70.3 (d, 2JCP = 8.6 Hz), 125.6, 130.7 (×2), 
132.0 (×2), 140.5. 
31P NMR (160 MHz, CDCl3) δ 56.7, 62.0. 
Anal Cacld for C8H7P3S8: C, 21.23; H, 1.56. Found: C, 21.09; H, 1.77. 
Mp (dec.): 184.2–184.7 °C 
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7-(2-Methoxyphenyl)-2,4,6,8,9-pentathia-1,3,5-triphosphaadamantane-1,3,5-trisulfide (55b) 
 
According to the general procedure A, 55b was synthesized from 2’-methoxyacetophenone 54b (338 
mg, 2.25 mmol) to give a colorless crystal (146 mg, 14%).  
55b 
HR-MS (ESI): m/z Calcd for C9H10OP3S8 [M+H]+: 482.7710, found: 482.7699. 
IR (KBr, cm-1): 2935, 2914, 2833, 1459, 756, 687, 532. 
1H NMR (400 MHz, CDCl3): δ 3.39 (d, 2JHP = 10.0 Hz, 2H), 3.94 (s, 3H), 7.10 (d, J = 8.0 Hz, 1H), 7.14 
(dd, J = 8.0, 8.0 Hz, 1H), 7.54 (dd, J = 8.0, 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ 42.5 (d, 1JCP = 50.6 Hz), 56.3, 70.1 (d, 2JCP = 8.6 Hz), 114.0, 122.0, 126.62, 
126.64, 133.0, 157.7. 
31P NMR (160 MHz, CDCl3) δ 56.2, 63.1. 
Anal Cacld for C9H9OP3S8: C, 22.40; H, 1.88. Found: C, 22.66; H, 2.12. 
Mp (dec.): 180.2–180.8 °C 
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7-(o-Tolyl)-2,4,6,8,9-pentathia-1,3,5-triphosphaadamantane-1,3,5-trisulfide (55c) 
 
According to the general procedure 1, 55c was synthesized from 2’-methylacetophenone 54c (302 mg, 
2.25 mmol) to give a colorless crystal (146 mg, 10%). 
55c 
HR-MS (ESI): m/z Calcd for C9H10P3S8 [M+H]+: 466.7761, found: 466.7747. 
IR (KBr, cm-1): 2916, 2885, 2861, 1459, 1389, 758, 689, 527. 
1H NMR (400 MHz, CDCl3): δ 2.68 (s, 3H), 3.21 (d, 2JHP = 11.6 Hz, 2H), 7.37 – 7.51 (m, 4H). 
13C NMR (100 MHz, CDCl3): δ 23.3, 44.2 (d, 1JCP = 53.4 Hz), 70.6 (d, 2JCP = 9.5 Hz), 125.2, 127.8, 
131.4, 135.9, 138.6, The ipso carbon peak was not observed.  
31P NMR (160 MHz, CDCl3) δ 56.6, 60.3. 
Anal Cacld for C9H9P3S8: C, 23.17; H, 1.94. Found: C, 23.02; H, 2.09. 
Mp (dec.): 166.2–166.7 °C 
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7-(3-Tolyl)-2,4,6,8,9-pentathia-1,3,5-triphosphaadamantane-1,3,5-trisulfide (55g) 
 
According to the general procedure 1, 55g was synthesized from 3’-methylacetophenone 54g (302 mg, 
2.25 mmol) to give a colorless crystal (480 mg, 46%). 
55g 
HR-MS (ESI): m/z Calcd for C9H10P3S8 [M+H]+: 466.7761, found: 466.7762. 
IR (KBr, cm-1): 2915, 2865, 1459, 1389, 780, 692, 533. 
1H NMR (400 MHz, CDCl3): δ 2.45 (s, 3H), 3.13 (d, 2JHP = 10.8 Hz, 2H), 7.36 – 7.49 (m, 4H). 
13C NMR (100 MHz, CDCl3): δ 21.8, 42.8 (d, 1JCP = 54.4 Hz), 122.4, 126.1, 130.5, 132.8, 141.0, The 
ipso carbon peak and the quaternary carbon peak were not observed.  
31P NMR (160 MHz, CDCl3) δ 56.8, 62.2. 
Anal Cacld for C9H9P3S8: C, 23.17; H, 1.94. Found: C, 23.21; H, 1.98. 
Mp (dec.): 168.6–168.7 °C 
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7-(3-Bromophenyl)-2,4,6,8,9-pentathia-1,3,5-triphosphaadamantane-1,3,5-trisulfide (55h) 
 
According to the general procedure 1, 55h was synthesized from 3’-bromoacetophenone 54h (448 mg, 
2.25 mmol) to give a colorless amorphous material (356 mg, 29%).  
55h  
HR-MS (ESI): m/z Calcd for C8H779BrP3S8 [M+H]+: 530.6710, found: 530.6731. 
IR (KBr, cm-1): 2918, 2871, 1470, 1077, 795, 689, 564, 536. 
1H NMR (400 MHz, CDCl3): δ 3.10 (d, 2JHP = 10.8 Hz, 2H), 7.47 (dd, J = 8.0, 8.0 Hz, 1H), 7.59 (d, J = 
8.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.76 – 7.78 (m, 1H). 
13C NMR (100 MHz, CDCl3): δ 42.6 (d, 1JCP = 54.4 Hz), 69.5 (d, 2JCP = 7.6 Hz), 124.2, 124.7, 128.7, 
132.0, 135.1, 142.4. 
31P NMR (160 MHz, CDCl3) δ 55.7, 61.0. 
Anal Cacld for C8H6BrP3S8: C, 18.08; H, 1.14. Found: C, 17.96; H, 1.28. 
Mp (dec.): 181.8–182.5 °C 
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7-(3-Nitrophenyl)-2,4,6,8,9-pentathia-1,3,5-triphosphaadamantane-1,3,5-trisulfide (55i) 
 
According to the general procedure 1, 55i was synthesized from 3’-nitroacetophenone 54i (372 mg, 2.25 
mmol) to give a pale-yellow crystal (137 mg, 10%). 
55i 
HR-MS (ESI): m/z Calcd for C8H7NO2P3S8 [M+H]+: 497.7455, found: 497.7478. 
IR (KBr, cm-1): 2926, 2868, 1523, 1459, 1348, 778, 696, 533. 
1H NMR (400 MHz, CDCl3): δ 3.18 (d, 2JHP = 11.2 Hz, 2H), 7.84 (dd, J = 8.0, 8.0 Hz, 1H), 8.03 (dd, J 
= 8.0, 2.0 Hz, 1H), 8.46 (dd, J = 8.0, 2.0 Hz, 1H), 8.51 (dd, J = 2.0, 2.0 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ 42.6 (d, 1JCP = 54.3 Hz), 69.5 (d, 2JCP = 7.6 Hz), 120.9, 126.6, 131.8, 
132.0, 142.5, 149.3. 
31P NMR (160 MHz, CDCl3) δ 54.8, 60.1. 
Anal Cacld for C8H6NO2P3S8: C, 19.31; H, 1.22; N, 2.81. Found: C, 19.24; H, 1.39; N, 2.89. 
Mp (dec.): 196.0–196.8 °C 
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7-(4-Methoxyphenyl)-2,4,6,8,9-pentathia-1,3,5-triphosphaadamantane-1,3,5-trisulfide (55j) 
 
According to the general procedure 2, 55j was synthesized from 4’-methoxyacetophenone 54j (129 
mg, 0.860 mmol) to give a colorless crystal (60 mg, 14%).  
55j 
HR-MS (ESI): m/z Calcd for C9H10OP3S8 [M+H]+: 482.7710, found: 482.7723. 
IR (KBr, cm-1): 2918, 2863, 2832, 1459, 684, 530. 
1H NMR (400 MHz, CDCl3): δ 3.09 (d, 2JHP = 11.0 Hz, 2H), 3.88 (s, 3H), 7.06 (d, J = 8.8 Hz, 2H), 7.55 
(d, J = 8.8 Hz, 2H). 
13C NMR (100 MHz, CDCl3): δ 42.8 (d, 1JCP = 53.4 Hz), 55.9, 69.9 (dd, 2JCP = 16.2 Hz, 2JCP = 7.7 Hz), 
115.9 (×2), 127.2 (×2), 132.3 (ddd, 3JCP = 21.1 Hz, 3JCP = 8.1 Hz, 3JCP = 8.1 Hz), 162.1. 
31P NMR (160 MHz, CDCl3) δ 57.5, 62.6. 
Anal Cacld for C9H9OP3S8: C, 22.40; H, 1.88. Found: C, 22.15; H, 2.09. 
Mp (dec.): 165.7–166.5 °C 
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7-(4-Tolyl)-2,4,6,8,9-pentathia-1,3,5-triphosphaadamantane-1,3,5-trisulfide (55k) 
 
According to the general procedure 1, 55k was synthesized from 4’-methylacetophenone 54k (302 mg, 
2.25 mmol) to give a colorless crystal (408 mg, 38%). 
55k 
HR-MS (ESI): m/z Calcd for C9H10P3S8 [M+H]+: 466.7761, found: 466.7755. 
IR (KBr, cm-1): 2916, 2864, 1459, 1389, 805, 681, 527. 
1H NMR (400 MHz, CDCl3): δ 2.44 (s, 3H), 3.11 (d, 2JHP = 11.0 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 7.51 
(d, J = 8.4 Hz, 2H). 
13C NMR (100 MHz, CDCl3): δ 21.5, 42.8 (d, 1JCP = 53.4 Hz), 70.1 (d, 2JCP = 8.6 Hz), 125.4 (×2), 131.3 
(×2), 137.6, 142.7. 
31P NMR (160 MHz, CDCl3) δ 57.1, 62.3. 
Anal Cacld for C9H9P3S8: C, 23.17; H, 1.94. Found: C, 22.97; H, 2.04. 
Mp (dec.): 171.4–171.7 °C 
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7-(4-Bromophenyl)-2,4,6,8,9-pentathia-1,3,5-triphosphaadamantane-1,3,5-trisulfide (55l) 
 
According to the general procedure 2, 55l was synthesized from 4’-bromoacetophenone 54l (171 mg, 
0.860 mmol) to give a colorless crystal (90 mg, 32%). 
55l 
HR-MS (ESI): m/z Calcd for C8H779BrP3S8 [M+H]+: 530.6710, found: 530.6706. 
IR (KBr, cm-1): 2924, 2876, 1459, 1077, 809, 693, 534, 528. 
1H NMR (400 MHz, CDCl3): δ 3.09 (d, 2JHP = 11.6 Hz, 2H), 7.51 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 8.6 
Hz, 2H). 
13C NMR (100 MHz, CDCl3): δ 42.6 (d, 1JCP = 54.4 Hz), 69.3 – 69.6 (m), 126.7, 127.2 (×2), 133.9 (×2), 
The ipso carbon peak was not observed. 
31P NMR (160 MHz, CDCl3) δ 56.0, 61.3. 
Anal Cacld for C8H6BrP3S8: C, 18.08; H, 1.14. Found: C, 17.91; H, 1.30. 
Mp (dec.): 205.2–205.6 °C 
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7a-(2-Methoxyphenyl)dihydro-2,6-epithio[1,2,5]thiadiphospholo[2,3-d][1,3,2,4]dithia-
diphosphole 2,4,6-trisulfide (59) 
 
Under Ar atmosphere, 2’-methoxyacetophenone 54b (129 mg, 0.860 mmol) and P4S10 (3.82 g, 8.60 
mmol) in toluene (5 mL) were suspended and stirred at refluxing temperature for 20 h. The reaction 
mixture was filtered through an 11G-4 glass filter and washed with CHCl3 (80 mL). The filtrate was 
evaporated in vacuo, and then the residue was purified by recrystallization from hexane/CHCl 3 to give 
59 (76 mg, 5%) as a colorless crystal. 
 
59 
HR-MS (ESI): m/z Calcd for C9H10OP3S7 [M+H]+: 450.7989, found: 450.7992. 
IR (KBr, cm-1): 2929, 2912, 2826, 1459, 750, 692, 528. 
1H NMR (400 MHz, CDCl3): δ 3.38 (ddd, 2JHP = 39.6 Hz, 14.4 Hz, 3JHP = 10.4 Hz, 1H), 3.87 (s, 3H), 
4.46 (dd, J = 14.4 Hz, 2JHP = 12.0 Hz, 1H), 7.03 (d, J = 8.0 Hz, 1H), 7.09 (dd, J = 7.4, 7.4 Hz, 1H), 7.35 
– 7.40 (m, 1H), 7.49 – 7.54 (m, 1H). 
13C NMR (100 MHz, CDCl3): δ 55.2 (dd, 1JCP = 50.3 Hz, 2JCP = 11.4 Hz), 55.6, 113.0 (d, J = 2.9 Hz), 
119.9 – 120.0 (m), 121.8 (d, J = 2.0 Hz), 126.9 (d, J = 6.7 Hz), 132.7 (d, J = 3.8 Hz), 156.7 (d, J = 4.7 
Hz), The quaternary carbon peak was not observed. 
31P NMR (160 MHz, CDCl3) δ 55.0, 69.8, 124.1. 
Anal Cacld for C9H9OP3S7: C, 23.99; H, 2.01. Found: C, 23.83; H, 2.09. 
Mp (dec.): 213.9–214.4 °C 
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Thionation of ketone and amide with 55a 
 
4, 4’-Dimethoxy-thiobenzophenone (61) 
 
A mixture of 60 (25.0 mg, 0.105 mmol) and 55a (29.0 mg, 0.0630 mmol) in toluene (2 mL) was stirred 
under refluxing temperature for 6 h. After the evaporation of the solvent, the residue was purified by 
silica gel column chromatography (Hexane:EtOAc = 30:1) to give 61 as a dark blue solid (26.6 mg, 
98%). 
The spectral data were in agreement with the literature.  38 
 
N, N-Dimethyl-thiobenzamide (63) 
 
A mixture of 62 (28.0 mg, 0.188 mmol) and 55a (51.0 mg, 0.113 mmol) in toluene (2 mL) was stirred 
under refluxing temperature for 6 h. After the evaporation of the solvent, the residue was purified by 
silica gel column chromatography (Hexane:EtOAc = 30:1) to give 63 as a dark blue solid (27.8 mg, 
89%). 
The spectral data were in agreement with the literature.  39 
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Crystal structure of 55a 
 
 
 
 
 
 
 
 
 
 
Crystal data and structural refinement parameters for 55a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 55a 
Data deposition CCDC 1539583 
Empirical formula C8H7P3S8 
Formula weight 452.54 
Temperature 173 K 
Wavelength 0.71075 Å 
Crystal system monoclinic 
Space group P21/n 
Unit cell dimensions   a 17.832(13) Å 
                   b 10.324(7) Å 
                   c 18.638(13) Å 
                    90.0000 º 
                     100.23(1) º 
                    90.0000 º 
Volume 3377(4) Å3 
Z 8 
Density (calculated) 1.780 g/m3 
Absorption coefficient Mu 1.322 mm−1 
F(000) 1824.00 
Crystal size 0.400.2000.100 mm3 
Theta range for data collection 2.22 º to 27.49 º 
Index ranges −23<=h<=23 
 −13<=k<=13 
 −24<=l<=24 
Reflections collected 32217 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 7697/0/343 
Goodness-of-fit on F2 1.103 
Final R indices R1 = 0.0850 [I>2(I)] , wR2 = 0.2235 (all data) 
55a (mol-2) 55a (mol-1) 
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Crystal structure of 55c 
 
 
 
 
 
 
 
 
 
 
 
Crystal data and structural refinement parameters for 55c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 55c 
Data deposition CCDC 1539584 
Empirical formula C9H9P3S8 
Formula weight 466.57 
Temperature 173 K 
Wavelength 0.71075 Å 
Crystal system monoclinic 
Space group P21/c 
Unit cell dimensions   a 10.309(18) Å 
                   b 19.24(3) Å 
                   c 9.277(16) Å 
                    90.0000 º 
                     98.332(19) º 
                    90.0000 º 
Volume 1821(5) Å3 
Z 4 
Density (calculated) 1.702 g/m3 
Absorption coefficient Mu 1.229 mm−1 
F(000) 944.00 
Crystal size 0.6000.2000.200 mm3 
Theta range for data collection 2.458 º to 27.532 º 
Index ranges −13<=h<=13 
 −24<=k<=24 
 −12<=l<=11 
Reflections collected 18488 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 4121/0/197 
Goodness-of-fit on F2 1.022 
Final R indices R1 = 0.0368 [I>2(I)] , wR2 = 0.0878 (all data) 
55c 
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Crystal structure of 55i 
 
 
 
 
 
 
 
 
 
 
Crystal data and structural refinement parameters for 55i. 
 
 
Compound 55i 
Data deposition CCDC 1530903 
Empirical formula C8H6NO2P3S8 
Formula weight 497.54  
Temperature 173 K 
Wavelength 0.71075 Å 
Crystal system triclinic 
Space group P−1 
Unit cell dimensions   a 8.326(7) Å 
                   b 9.126(8) Å 
                   c 12.009(10) Å 
                    78.679(19) º 
                     79.57(2) º 
                    88.42(3) º 
Volume 879.9(13) Å3 
Z 2 
Density (calculated) 1.16 g/m3 
Absorption coefficient Mu 1.287 mm−1 
F(000) 500.00 
Crystal size 0.3000.2000.120 mm3 
Theta range for data collection 2.777 º to 27.758 º 
Index ranges −10<=h<=10 
 −11<=k<=11 
 −15<=l<=15 
Reflections collected 9580 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 4070/0/199 
Goodness-of-fit on F2 1.014 
Final R indices R1 = 0.0368 [I>2(I)] , wR2 = 0.1033 (all data) 
55i 
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Crystal structure of 59. Only one set of atoms for the disordered CH2 [C(1)] and S [S(7)] is shown. 
 
 
 
 
 
 
 
 
 
 
Crystal data and structural refinement parameters for 59. 
 
  
Compound 59 
Data deposition CCDC 1507779 
Empirical formula C9H9P3S7 
Formula weight 450.51 
Temperature 153 K 
Wavelength 1.5487  
Crystal system monoclinic 
Space group P21/c 
Unit cell dimensions   a 9.35466(17) Å 
                       b 13.3056(2) Å 
                       c 14.1327(3) Å 
                        90.0000 º 
                         105.2020(7) º 
                        90.0000 º 
Volume 1697.53(5) Å3 
Z 4 
Density (calculated) 1.763 g/m3 
Absorption coefficient Mu 11.201 mm−1 
F(000) 912.00 
Crystal size 0.2500.2500.100 mm3 
Theta range for data collection 4.643 º to 68.233 º 
Index ranges −11<=h<=11 
 −16<=k<=16 
 −16<=l<=16 
Reflections collected 29812 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 3105/0/194 
Goodness-of-fit on F2 0.965 
Final R indices R1 = 0.0333 [I>2(I)] , wR2 = 0.1141 (all data) 
59 
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Pharmacology 
 
Opioid Receptor Binding  
CHO cells stably expressing human were purchased from ChanTest Co.; these cell membranes were 
used for opioid receptor binding assay. Binding affinity for μ, δ, or κ opioid receptor in test compounds 
was measured by displacement of [3H]-DAMGO, [3H]-DPDPE, or [3H]-U69,593 (each 2 nM), 
respectively. Nonspecific binding was measured in the presence of 10 μM unlabeled DAMGO, DPDPE, 
or U-69,593. Radioactivity in the test samples was determined by a MicroBeta scintillation counter with 
96-well microplate (PerkinElmer). The value of each test sample was calculated as [(T1 – T0)/(T2 – T0)] 
× 100, where T0 is the nonspecific binding, T1 is the [3H]-labeled ligand binding in the presence of 
various concentrations of test compounds (10–5–10–11 M), and T2 is the [3H]-labeled ligand binding in 
the absence of respective test compounds. Sigmoidal concentration–response curve and Ki values were 
calculated by Prism software (version 6.05). 
 
[35S]-GTPγS binding assay 
Cell membranes were obtained from CHO cells expressing human μ, δ, or κ opioid receptor by 
homogenization and centrifuge. Membrane suspension was incubated in assay buffer with various 
concentrations of test compounds, GDP and [35S]-GTPγS (0.1 nM). Non-specific binding was measured 
in the presence of 10 μM unlabeled GTPγS. Radioactivity in the samples was determined using a 
MicroBeta scintillation counter with 96-well microplate. G-protein activation by test compounds was 
expressed by % G-protein activation, which was calculated as (T1 – T0)/(T2 – T0) × 100, where T0 is the 
non-specific activity, T1 is the [35S]-GTPγS activity in the presence of various concentration of test 
compounds and T2 is the [35S]-GTPγS activity in the absence of the test compounds. Sigmoidal 
concentration–response curve, Emax value and EC50 value were calculated by Prism software. 
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